Affolter, Burt, Stanley. Aguilar, - Molecular...

AUTHOR INDEX FOR VOLUME 22

803

A

Abell, Creed W. See Denney, Patel, and Fritz, 500

Abita, Jean-Pierre. See Gespach, Saal, and Cost, 547

Adams, Stephen M., and Kaminsky, Laurence S. Molecular Orbital

Studies of Epoxide Stability of Carcinogenic Polycyclic Aromatic

Hydrocarbon Diol Epoxides, 459

Adler, A. See Scheibel, 140

Affolter, Hubert, and Pletscher, Alfred. Storage ofBiogenic Amines

in Intact Blood Platelets of Man: Dependence on a Proton Gra-

dient, 94

Aguilar, Jos#{233} S., Salas, Pedro J. I., and De Robertis, Eduardo.

Cholinergic Muscannic Receptor in Synaptosomal Membranes:

Heterogeneity of Binding Sites for L-[H]Quinuclidinyl Benzilate,

304

Aktories, Klaus. See Grandt and Jakobs, 320

Albuquerque, Edson X.See Maleque, Souccar, and Cohen, 636

See Warnick, Jessup, Overman, Eldefrawi, Nimit, and Daly, 565

See Warnick, Maleque, Bakry, and Eldefrawi, 82

Alvares, Alvito P. See Ueng, 221

Anderson, Wendie. See Loew, Hashimoto, Williamson, and Burt,

667

Andersson, Bo, Nordenskj#{246}ld, Magnus, Rahimtula, Anver, and

Mold#{233}us, Peter. Prostaglandin Synthetase-Catalyzed Activation

of Phenacetin Metabolites to Genotoxic Products, 479

Asao, Yukari. See Suketa, Yamada, and Hasegawa, 116

Aslaman, Dimitrina, and de Cheveign#{233}, Suzanne. Inelastic Elec-

tron Tunneling Spectroscopic Study of Interaction of Acetylcho-

line and ,G-Methyl Acetylcholine with Alumina Surface, 678

B

Bader, Hermann. See Gietzen and W#{252}thrich, 413

Baguley, Bruce C., and Cain, Bruce F. Comparison of the in Vito

and in Vitro Antileukemic Activity ofMonosubstituted Derivatives

of 4’-(9-Acridinylamino)methanesulfon-m-anisidide, 486

Bakry, Nabil

Eldefrawi, Ainira T., Eldefrawi, Mohyee E., and Riker, Walter

F., Jr. Interactions of Quaternary Ammonium Drugs with Acetyl-

cholinesterase and Acetyicholine Receptor of Torpedo Electric

Organ, 63

See Warnick, Maleque, Eldefrawi, and Albuquerque, 82

Barber, R. See Clark, Goka, Green, and Butcher, 609

Barsuhn, C. See Cheney, Lahti, and Gay, 349

Batzri, Shmuel

Harmon, John W., and Thompson, William F. Interaction of

Histamine with Gastric Mucosal Cells: Effect of Histamine Ago-

nists on Binding and Biological Response, 33

Harmon, John W., Dyer, Jean, and Thompson, William F.

Interaction of Histamine with Gastric Mucosal Cells: Effect of

Histamine H2 Antagonists on Binding and Biological Response, 41

Baxter, Diane. See Fischer, 231

Beaujouan, J. C., Torrens, Y., Herbet, A., Daguet, M.-C., Glow-

inski, J., and Proehiantz, A. Specific Binding of an Immuno-

reactive and Biologically Active ‘251-Labeled Substance P Deriva-

tive to Mouse Mesencephalic Cells in Primary Culture, 48

Beiderman, Barry. See Bourne, Steinberg, and Brothers, 204

Bend, John R. See Wolf, Statham, McMenamin, Boyd, and Philpot,

738

Boulenger, Jean-Philippe. See Marangos, Patel, and Clark-Rosen-

berg, 26

Bourne, Henry R., Beiderman, Barry, Steinberg, Florence, and

Brothers, Virginia M. Three Adenylate Cyclase Phenotypes in

S49 Lymphoma Cells Produced by Mutations of One Gene, 204

Boyd, Michael R. See Wolf, Statham, McMenamin, Bend, and Phil-

pot, 738

Boyle, Michael R. See Hughes, Brown, Taylor, and Insel, 258

Brothers, Virginia M. See Bourne, Beiderman, and Steinberg, 204

Brown, Oliver E. See Seduick, Hamrell, and Laszlo, 766

Brown, R. Dale. See Hughes, Boyle, Taylor, and Insel, 258

Brune, K. See Mehler and Habicht, 525

Burt, Stanley. See Loeu’, Hashimoto, Williamson, and Anderson,

667

Butcher, R. W. See Clark, Goka, Green, and Barber, 609

C

Cain, Bruce F. See Baguley, 486

Camus, J. See Chatelain, Robberecht, Waelbroeck, De Neef, and

Christophe, 342

Caron, Marc G.

See De Lean and Kilpatrick, 290

See Kilpatrick and De Lean, 298

Carter, Timothy H. See Rose and Leonard, 517

Catterall, William A.

See Costa, 196

See Willow, 627

Cech, Stella Y., and Maguire, Michael E. Magnesium Regulation of

the Beta-Receptor-Adenylate Cyclase Complex. I. Effects of Man-

ganese on Receptor Binding and Cyclase Activation, 267

Chatelain, P., Robberecht, P., Waelbroeck, M., De Neef, P., Ca-

mus, J., and Christophe, J. Thermodependence of Guanine

Nucleotide-Activated Rat Cardiac Adenylate Cyclase Activity: Ef-

fect of Cholera Toxin Pretreatment, 342

Cheney, B. V., Lahti, R. A., Barsuhn, C., and Gay, D. D. An

Analysis of Binding at the Opioid Receptor Based upon an Ago-

nist/Antagonist Two-State Model, 349

Cho, A. K. See Duncan, 235

Cho, Arthur K., Maynard, Michael S., Matsumoto, Richard M.,

Lindeke, Bj#{246}rn, Paulsen, Ulla, and Miwa, Gerald T. The

Opposing Effects of N-Hydroxyamphetamine and N-Hydroxy-

phentermine on the H2O2 Generated by Hepatic Cytochrome P-

450, 465

Christophe, J. See Chatelain, Robberecht, Waelbroeck, De Neef, and

Camus, 342

Chwang, T. Ling. See Roberts, Franklin, Odom, and Peck, 760

Clark, R. B., Goka, T. J., Green, D. A., Barber, R., and Butcher,

R. W. Differences in the Forskolin Activation of Adenylate Cy-

clases in Wild-Type and Variant Lymphoma Cells, 609

Clark-Rosenberg, Reena. See Marangos, Patel, and Boulenger, 26

Clement-Cormier, Yvonne C. See Suen and Kwan, 595

Cohen, Jonathan B. See Maleque, Souccar, and Albuquerque, 636

Coffins, Allan C. See Marks, 554

Conney, Allen H. See Vyas, Levin, Yagi, Thakker, Ryan, Thomas,

and Jerina, 182

Conway, J. G., Kauffman, F. C., Ji, S., and Thurman, R. G. Rates

of Sulfation and Glucuronidation of 7-Hydroxycoumarin in Pen-

portal and Pericentral Regions of the Liver Lobule, 509

Cost, H#{233}l#{232}ne.See Gespach, Saal, and Abita, 547

Costa, Maria R., and Catterall, William A. Characterization of

Variant Neuroblastoma Clones with Missing or Altered Sodium

Channels, 196

Covey, Douglas F. See Klunk and Ferrendelli, 431, 438, 444

Crippen, Gordon M. Distance Geometry Analysis of the Benzodiaze-

pine Binding Site, 11

804 AUTHOR IN1)EX

Crooke, Stanley T. See Long, Willis, and Prestayko, 152

D

Daguet, M.-C. See Beaujouan, Torrens, Herbet, Glowinski, and Pro-

chiantz, 48

Dalmark, Mads, and Johansen, Peter. Molecular Association be-

tween Doxorubicin (Adriamycin) and DNA-Derived Bases, Nu-

cleosides, Nucleotides, Other Aromatic Compounds, and Proteins

in Aqueous Solution, 158

Daly, John W. See Warnick, Jessup, Overman, Eldefrawi, Nimit,

and Albuquerque, 565

Dannan, Ghazi A., and Guengerich, F. Peter. Immunochemical

Comparison and Quantitation of Microsomal Flavin-Containing

Monooxygenases in Various Hog, Mouse, Rat, Rabbit, Dog, and

Human Tissues, 787

Dax, Elizabeth M., and Partilla, John S. Adrenergic Ligand Lipo-

solubiity in Membranes: Direct Assessment in a Beta-Adrenergic

Binding System, 5

de Cheveign#{233}, Suzanne. See Aslanian, 678

De Lean, Andre

Kilpatrick, Brian F., and Caron, Marc G. Dopamine Receptor of

the Porcine Anterior Pituitary Gland: Evidence for Two Affinity

States Discriminated by Both Agonists and Antagonists, 290

See Kilpatrick and Caron, 298

See Vale, Lefkowitz, and Stadel, 619

De Neef, P. See Chatelain, Robberecht, Waelbroeck, Camus, and

Christophe, 342

Denney, Richard M., Patel, Nutan T., Fritz, Richard R., and

Abell, Creed W. A Monoclonal Antibody Elicited to Human

Platelet Monoamine Oxidase: Isolation and Specificity for Human

Monoamine Oxidase B but Not A, 500

De Robertis, Eduardo. See Aguilar and Salas, 304

Diaham, Babou. See Gruenwedel, 121

Duncan, J. D., and Cho, A. K. N-Oxidation of Phentermine to N-

Hydroxyphentermine by a Reconstituted Cytochrome P-450 Oxi-

dase System from Rabbit Liver, 235

Dyer, Jean. See Batzri, Harmon, and Thompson, 41

E

Eldefrawi, Amira T.

Miller, E. Roxanne, Murphy, Deidre L., and Eldefrawi, Mohyee

E. [‘H]Phencyclidine Interactions with the Nicotinic Acetylcholine

Receptor Channel and Its Inhibition by Psychotropic, Antipsy-

chotic, Opiate, Antidepressant, Antibiotic, Antiviral, and Antiar-

rhythmic Drugs, 72

See Bakry, Eldefrawi, and Riker, 63

See Warnick, Maleque, Bakry, and Albuquerque, 82

Eldefrawi, Mohyee E.

See Bakry, Eldefrawi, and Riker, 63

See Eldefrawi, Miller, and Murphy, 72

See Warnick, Jessup, Overman, Nimit, Daly, and Albuquerque, 565

Epand, Richard M. Cation-Induced Conformational Change in Glu-

cagon, 105

Erickson, Leonard C. See Ramonas and McManus, 175

F

Fain, John N. See Litosch, Hudson, Mills, and Li, 109

Ferrendelli, James A. See Kiunk and Covey, 431, 438, 444

Fischer, Paul H., and Baxter, Diane. Enzyme Regulatory Site-

Directed Drugs: Modulation of Thymidine Triphosphate Inhibi-

tion of Thymidine Kinase by 5’-Amino-5’-deoxythymidine, 231

Franklin, Paula. See Roberts, Odom, Peck, and Chwang, 760

Fritz, Richard R. See Denney, Pate!, and Abel!, 500

G

Gay, D. D. See Cheney, Lahti, and Barsuhn, 349

Gespach, Christian, Saal, Fortuna, Cost, H#{233}l#{232}ne,and Abita,

Jean-Pierre. Identification and Characterization of Surface Re-

ceptors for Histamine in the Human Promyelocytic Leukemia Cell

Line HL-60: Comparison with Human Peripheral Neutrophils, 547

Gewirtz, David A., Randolph, Joyce K., and Goldman, I. David.

Catecholamine-Induced Release of the Folic Acid Analogue, Meth-

otrexate, from Rat Hepatocytes in Suspension: An Alpha-Adre-

nergic Phenomenon, 493

Gietzen, Klaus, W#{252}thrich, Andreas, and Bader, Hermann. Effects

of Microtubular Inhibitors on Plasma Membrane Calmodulin-De-

pendent Ca2�-Transport ATPase, 413

Glaumann, Hans. See Thomas, Ryan, von Bahr, and Levin, 190

Glowinski, J. See Beaujouan, Torrens, Herbet, Daguet, and Pro-

chiantz, 48

Goka, T. J. See Clark, Green, Barber, and Butcher, 609

Goldman I. David. See Gewirtz and Randolph, 493

Goren, H. J. See Hanif, Hollenberg, and Lederis, 381

Gorissen, H. See Ilien and Laduron, 243

Grandt, R#{252}diger, Aktories, Klaus, and Jakobs, Karl H. Guanine

Nucleotides and Monovalent Cations Increase Agonist Affinity of

Prostaglandin E2 Receptors in Hamster Adipocytes, 320

Green, D. A. See Clark, Goka, Barber, and Butcher, 609

Gruenwedel, Dieter W., and Diaham, Babou. Methylmercury(II)-

Induced Histone Perturbations in Nuclei Isolated from Calf Thy-

mus, 121

Grunewald, Gary L. See Rafferty, 127

Guengerich, F. Peter. See Dannan, 787

Gylfe, Erik, and Heliman, Bo. Lack of Ca2� Ionophoretic Activity of

Hypoglycemic Sulfonylureas in Excitable Cells and Isolated Secre-

tory Granules, 715

H

Habicht, J. See Mehier and Brune, 525

Hamrell, Michael. See Sedwick, Brown, and Laszlo, 766

Hamf, K., Goren, H. J., Hollenberg, M. D., and Lederis, K. Oxy-

tocin Action: Mechanisms for Insulin-Like Activity in Isolated Rat

Adipocytes, 381

Harden, T. Kendall. See Meeker, 310

Harmon, John W.

See Batzri and Thompson, 33

See Batzri, Dyer, and Thompson, 41

Harrelson, Willard G., Jr., and Mason, Ronald P. Microsomal

Reduction of Gentian Violet: Evidence for Cytochrome P-450-

Catalyzed Free Radical Formation, 239

Harris, R. Adron. See Stokes, 99

Hasegawa, Jun. See Suketa, Yamada, and Asao, 116

Hashimoto, Gail. See Loew, Williamson, Burt, and Anderson, 667

Helhnan, Bo. See Gylfe, 715

Herbet, A. See Beaujouan, Torrens, Daguet, Glowinski, and Pro-

chiantz, 48

Hidaka, Hiroyoshi

See Tanaka and Ohmura, 403

See Tanaka, Ohmura, and Yamakado, 408

Hirsch, James D. See Kochman, 335

Hnatowich, Mark, and LaBella, Frank S. Light-Enhanced Inhibi-

tion of Ouabain Binding to Digitalis Receptor in Rat Brain and

Guinea Pig Heart by the Food Dye Erythrosine, 687

Hollenberg, M. D. See Hanif, Goren, and Lederis, 381

Hom, D. S. See Law and Loh, 1

Houghton, Janet A., Tice, Arvil J., and Houghton, Peter J. The

Selectivity of Action of Methotrexate in Combination with 5-

Fluorouracil in Xenografts of Human Colon Adenocarcinomas, 771

Houghton, Peter J. See Houghton and Tice, 771

Hudson, Thomas H. See Litosch, Mills, Li, and Fain, 109

Hughes, Richard J., Boyle, Michael, R., Brown, R. Dale, Taylor,

Palmer, and Insel, Paul A. Characterization of Coexisting Al-

pha,- and Beta2-Adrenergic Receptors on a Cloned Muscle Cell

Line, BC3H-1, 258

men, B., Gorissen, H., and Laduron, P. M. Characterization of

Solubiized Serotonin (S2) Receptors in Rat Brain, 243

AUTHOR INDEX 805

Insel, Paul A.

See Hughes, Boyle, Brown, and Taylor, 258

See Snavely, 532

J

Jakobs, Karl H. See Grandt and Aktories, 320

Jefcoate, Colin R. See Keller and Turner, 451

Jerina, Donald M. See Vyas, Levin, Yagi, Thakker, Ryan, Thomas,

and Conney, 182

Jessup, Peter J. See Warnick, Overman, Eldefrawi, Nimit, Daly,


Ji, S. See Conway, Kauffman, and Thurman, 509

Johansen, Peter. See Dalmark, 158

Johnston, Colin I. See Woodcock, 589

Joost, Hans-Georg, and Steinfelder, Hans-Jurgen. Modulation of

Insulin Sensitivity by Adenosine: Effects on Glucose Transport,

Lipid Synthesis, and Insulin Receptors of the Adipocyte, 614

K

Kaiser, E. T. See Taylor and Miller, 657

Kaminsky, Laurence S. See Adams, 459

Kanter, Peter M., and Schwartz, Herbert S. A Fluorescence En-

hancement Assay for Cellular DNA Damage, 145

Kauffman, F. C. See Conway, Ji, and Thurman, 509

Kellar, Kenneth J. See Schwartz and McGee, 56

Keller, Gabriela M., Turner, Chris R., and Jefcoate, Colin R.

Kinetic Determinations of Benzo[a]pyrene Metabolism to Dihy-

driol Epoxides by 3-Methylcholanthrene-Induced Rat Liver Micro-

somes, 451

Kenimer, James G. See McGee, 360

Kharasch, Evan D., and Novak, Raymond F. Inhibition of Micro-

somal Oxidative Drug Metabolism by 1,4-Bis{2-[2-

hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione Diace-

tate, a New Antineoplastic Agent, 471

Kilpatrick, Brian F.

De Lean, Andre, and Caron, Marc G. Dopamine Receptor of the

Porcine Anterior Pituitary Gland: Effects of N-Ethylmaleimide

and Heat on Ligand Binding Mimic the Effects of Guanine Nu-

cleotides, 298

See De Lean and Caron, 290

Kioss, Michelle W. See Rosen and Rauckman, 529

Kiunk, Wiffiam E.

Covey, Douglas F., and Ferrendelli, James A. Anticonvulsant

Properties of a-, .�‘-, and a,y-Substituted �y-Butyrolactones, 438

Covey, Douglas F., and Ferrendeffi, James A. Comparison of

Epileptogenic Properties of Unsubstituted and fl-Alkyl-Substi-

tuted y-Butyrolactones, 431

Covey, Douglas F., and Ferrendeffi, James A. Structure-Activity

Relationships of Alkyl-Substituted y-Butyrolactones and Succini-

mides, 444

Kochman, Ronald L., and Hirsch, James D. Thermodynamic

Changes Associated with Benzodiazepine and Alkyl f3-Carboline-

3-carboxylate Binding to Rat Brain Homogenates, 335

Koivusaari, Ulla. See Peura, Mackenzie, and Lang, 721

Kwan, Peter C. K. See Suen and Clement-Cormier, 595

L

LaBella, Frank S. See Hnatowich, 687

Laduron, P. M. See Ilien and GorLssen, 243

Lahti, R. A. See Cheney, Barsuhn, and Gay, 349

Lang, Matti. See Peura, Mackenzie, and Koivusaari, 721

Laszlo, John See Sedwick, Hamrell, and Brown, 766

Law, P. Y., Horn, D. S., and Loh, H. H. Loss of Opiate Receptor

Activity in Neuroblastoma x Glioma NG1O8-15 Hybrid Cells after

Chronic Opiate Treatment: A Multiple-Step Process, 1

Lederis, K. See Hanif, Goren, and Hollenberg, 381

Lefl(owitz, Robert J. See Vale, De Lean, and Stadel, 619

Leonard, Thomas B. See Rose and Carter, 517

Levin, Wayne

See Thomas, Ryan, von Bahr, and Glaumann, 190

See Vyas, Yagi, Thakker, Ryan, Thomas, Conney, and Jerina, 182

Li, Shih-Ying. See Litosch, Hudson, Mills, and Fain, 109

Lindeke, Bj#{246}rn. See C/to, Maynard, Matsumoto, Paulsen, and Miwa,

465

Litosch, Irene, Hudson, Thomas H., Mills, Ira, Li, Shih-Ying, and

Fain, John N. Forskolin as an Activator of Cyclic AMP Accu-

mulation and Lipolysis in Rat Adipocytes, 109

Loew, Gilda, Hashimoto, Gail, Williamson, Lenita, Burt, Stanley,

and Anderson, Wendie. Conformational-Energy Studies of

Tetrapeptide Opiates: Candidate Active and Inactive Conforma-

tions, 667

Loh, H. H. See Law and Hom, 1

Lombardini, John B. See Sufrmn, 752

Long, Byron H., Willis, Charles E., Prestayko, Archie W., and

Crooke, Stanley T. Effect of Anthracycline Analogues on the

Appearance of Newly Synthesized Total RNA and Messenger

RNA in the Cytoplasm of Erythroleukemia Cells, 152

Lucier, George W. See Lui, Slaughter, and Philpot, 795

Lui, Edmund M. K., Slaughter, Shelley R., Philpot, Richard M.,

and Lucier, George W. Endocrine Regulation of Cadmium-Sen-

sitive Cytochrome P-450 in Rat Liver, 795

Lukovits, Istv#{225}n. A Theorem on de Novo Group Contributions, 725

M

MacDonald, Timothy, L. See Tachizau’a and Neal, 745

Macfarlane, Donald E.

Bidirectional Collision Coupling in the Regulation of the Adenylate

Cyclase: The Allozyme Hypothesis for Receptor Function, 580

and Stump, David C. Parallel Observation of the Occupancy of the

Alpha2-Adrenergic Receptor in Intact Platelets and Its Ability to

Inhibit the Adenylate Cyclase, 574

Mackenzie, Peter. See Peura, Koivusaari, and Lang, 721

Maguire, Michael E.

Magnesium Regulation of the Beta-Receptor-Adenylate Cyclase

Complex. II. Sc35 as a Mg2� Antagonist, 274

See Cech, 267

M#{228}hlmann, Horst. See Quast and Vollmer, 20

Maleque, Mohammed A.

Souccar, Caden, Cohen, Jonathan B., and Albuquerque, Edson

x. Meproadifen Reaction with the Ionic Channel of the Acetyl-

choline Receptor: Potentiation of Agonist-Induced Desensitization

at the Frog Neuromuscular Junction, 636

See Warnick, Bakry, Eldefrawi, and Albuquerque, 82

Malincomco, Scott M., and McCarl, Richard L Effect of Halothane

on Cardiac Sarcoplasmic Reticulum Ca2�-ATPase at Low Calcium

Concentrations, 8

Marangos, Paul J., Patel, Jitendra, Boulenger, Jean-Philippe,

and Clark-Rosenberg, Reena. Characterization of Peripheral-

Type Benzodiazepine Binding Sites in Brain Using [‘H]Ro 5-4864,

26

Maren, Thomas H. See Sanyal, Swenson, and Pessah, 211

Marks, Michael J., and Collins, Allan C. Characterization of Nico-

tine Binding in Mouse Brain and Comparison with the Binding of

a-Bungarotoxin and Quinuclidinyl Benzilate, 554

Markstein, R. See Seiler, 281

Mason, Ronald P.

See Harrelson, 239

See Mottley and Trice, 732

Matsumoto, Richard M. See Cho, Maynard, Lindeke, Paulsen, and

Miwa, 465

Maynard, Michael S. See Cho, Matsumoto, Lindeke, Paulsen, and

Miwa, 465

McCarl, Richard L. See Malinconico, 8

McGee, Richard, Jr.

and Kenimer, James G. The Effects of Exposure to Unsaturated

Fatty Acids on Opiate Receptors, Prostaglandin E, Receptors, and

806 AUTHOR INDEX

McGee, Richard, Jr.-continued

and Kenimer, James G.-continued

Adenylate Cyclase Activity of Neuroblastoma x Glioma Hybrid

Cells, 360

See Schwartz and Kellar, 56

McManus, Michael E. See Ramonas and Erickson, 175

McMenamin, Mary G. See Wolf, Statham, Bend, Boyd, and Phi Ipot,

738

Meeker, Rick B., and Harden, T. Kendall. Muscarinic Cholinergic

Receptor-Mediated Activation of Phosphodiesterase, 310

Mehler, E. L., Habicht, J., and Brune, K. Quantum Chemical

Analysis of Structure-Activity Relationships in Nonsteroidal Anti-

inflammatory Drugs, 525

Miller, E. Roxanne. See Eldefrawi, Murphy, and Eldefrawi, 72

Miller, Richard J. See Taylor and Kaiser, 657

Mills, Ira. See Litosch, Hudson, Li, and Fain, 109

Miwa, Gerald T. See Cho, Maynard, Matsumoto, Lindeke, and Paul-

sen, 465

Mold#{233}us, Peter. See Andersson, Nordenskjdld, and Rahimtula, 479

Mottley, Carolyn, Trice, Thomas B., and Mason, Ronald P. Direct

Detection of the Sulfur Trioxide Radical Anion during the Horse-

radish Peroxidase-Hydrogen Peroxide Oxidation of Sulfite

(Aqueous Sulfur Dioxide), 732

Murphy, Deirdre L. See Eldefrawi, Miller, and Eldefrawi, 72

Murphy, Kenneth M. M., and Snyder, Solomon H. Heterogeneity

of Adenosine A, Receptor Binding in Brain Tissue, 250

N

Nadler, Hana. See Nehmad and Simantov, 389

Neal, Robert A. See Tachizawa and MacDonald, 745

Nebert, Daniel W. See Tukey and Negishi, 779

Negishi, Masahiko. See Tukey and Nebert, 779

Nehmad, Rafael, Nadler, Hana, and Simantov, Rabi. Effects of

Acute and Chronic Morphine Treatment on Calmodulin Activity

of Rat Brain, 389

Nimit, Yuth. See Warnick, Jessup, Overman, Eldefrawi, Daly, and

Albuquerque, 565

Nordenskj#{246}ld, Magnus. See Andersson, Rahimtula, and Mold#{233}us,

479

Norman, Jon A., and Staehlin, Mattys. Calmodulin Inhibitors Ac-

tivate Glycogen Phosphorylase B to A Conversion in C6 Glioma

Cells, 395

Novak, Raymond F. See Kharasch, 471

0

Odom, Gina. See Roberts, Franklin, Peck, and C/twang, 760

Ohmura, Takehisa

See Tanaka and Hidaka, 403

See Tanaka, Yamakado, and Hidaka, 408

Overman, Larry E. See Warnick, Jessup, Eldefrawi, Nimit, Daly,


P

Partilla, John S. See Dax, 5

Patel, Jitendra. See Marangos, Boulenger, and Clark-Rosenberg, 26

Patel, Nutan T. See Denney, Fritz, and Abel!, 500

Paulsen, Ulla. See Cho, Maynard, Matsumoto, Lindeke, and Miwa,

465

Peck, Charles. See Roberts, Franklin, Odom, and Chwang, 760

Pennefather, Peter, and Quastel, David M. J. Modification of Dose-

Response Curves by Effector Blockade and Uncompetitive Antag-

onism, 369

Perez, David J., and Tattersall, Martin H. N. The Metabolic Basis

of Deoxyuridine Cytotoxicity: Studies of Cultured Human Lym-

phoblasts, 166

Pessah, Ness I. See Sanyal, Swenson, and Maren, 211

Peura, Pekka, Mackenzie, Peter, Koivusaari, Ulla, and Lang,

Matti. Increased Fluidity of a Model Membrane Caused by Tet-

rahydro-f.?-Carbolines, 721

Philpot, Richard M.

See Lui, Slaughter, and Lucier, 795

See Wolf, Statham, McMenamin, Bend, and Boyd, 738

Pletscher, Alfred. See Affolter, 94

Prestayko, Archie W. See Long, Willis, and Crooke, 152

Prochiantz, A. See Beaujouan, Torrens, Herbet, Daguet, and Glow-

inski, 48

Q

Quast, Ulrich, M#{228}hlmann, Horst, and Vollmer, Karl-Otto. Tem-

perature Dependence of the Benzodiazepine-Receptor Interaction,

20

Quastel, David M. J. See Pennefather, 369

R

Rafferty, Michael F., and Grunewald, Gary L. The Remarkable

Substrate Activity for Phenylethanolamine N-Methyltransferase

of Some Conformationally Defined Phenylethylamines Lacking a

Side-Chain Hydroxyl Group: Conformationally Defined Adrener-

gic Agents. 6, 127

Rahimtula, Anver. See Andersson, Nordenskj#{244}ld, and Mold#{233}us, 479

Ramonas, Lori M., Erickson, Leonard C., and McManus, Michael

E. The Effect of Misonidazole on the Cytotoxicity and DNA Cross-

Linking Activity of an Activated SuliIdocyclophosphamide in Hy-

poxic Mouse Leukemia Cells, 175

Randolph, Joyce K. See Gewirtz and Goldman, 493

Rauckman, Elmer J. See Rosen and Kioss, 529

Rautanen, P. K. See Vohra, 602

Retz, Konrad C., and Steele, William J. Mechanism of Inhibition of

Protein Synthesis by Morphine in Rat Brain and Liver, 706

Riker, Walter F., Jr. See Bakry, Eldefrawi, and Eldefrawi, 63

Robberecht, P. See Chatelain, Waelbroeck, De Neef, Camus, and

Christophe, 342

Roberts, DeWayne, Franklin, Paula, Odom, Gina, Peck, Charles,

and Chwang, T. Ling. Cytotoxicity of 5-Fluoro-5’-O-nitro-2’-de-

oxyuridine, a New Fluorinated Pyrimidine Derivative, in L1210

Cultures, 760

Rose, Kathleen M., Leonard, Thomas B., and Carter, Timothy H.

Effects of Adenine Nucleosides on RNA Synthesis in Adenovirus-

Infected Cells: 9-fl-D-Arabinofuranosyladenine as a Selective In-

hibitor of RNA Polyadenylation, 517

Rosen, Gerald M., Kloss, Michelle W., and Rauckman, Elmer J.

Initiation of in Vitro Lipid Peroxidation by N-Hydroxynorcocaine

and Norcocaine Nitroxide, 529

Rowe, Elizabeth S. The Effects of Ethanol on the Thermotropic

Properties of Dipalmitoylphosphatidylcholine, 133

Ryan, Dene E.

See Thomas, von Bahr, Glaumann, and Levin, 190

See Vyas, Levin, Yagi, Thakker, Thomas, Conney, and Jerina, 182

S

Saal, Fortuna. See Gespach, Cost, and Abita, 547

Saederup, Else. See Squires, 327

Salas, Pedro J. I. See Aguilar and De Robertis, 304

Sanyal, Gautam, Swenson, Erik R., Pessah, Ness I., and Maren,

Thomas H. The Carbon Dioxide Hydration Activity of Skeletal

Muscle Carbonic Anhydrase: Inhibition by Sulfonamides and An-

ions, 211

Scheibel, L. W., and Adler, A. Antimalarial Activity of Selected

Aromatic Chelators. III. 8-Hydroxyquinolines (Oxines) Substituted

in Positions 5 and 7, and Oxines Annelated in Position 5,6 by an

Aromatic Ring, 140

Schwartz, Herbert S. See Kanter, .145

Schwartz, Rochelle D., McGee, Richard, Jr., and Kellar, Kenneth

J. Nicotinic Cholinergic Receptors Labeled by [3H]Acetylcholine

in Rat Brain, 56

Sedwick, W. David, Hamrell, Michael, Brown, Oliver E., and

Laszlo, John. Metabolic Inhibition by a New Antifolate, 2,4-

Diamino-6- (2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]py-

AUTHOR INDEX 807

rimidine (BW3O1U), an Effective Inhibitor of Human Lymphoid

and Dihydrofolate Reductase-Overproducing Mouse Cell Lines,

766

Seiler, M. P., and Markstein, R. Further Characterization of Struc-

tural Requirements for Agonists at the Striatal Dopamine D-1

Receptor: Studies with a Series of Monohydroxyaminotetralins on

Dopamine-Sensitive Adenylate Cyclase and a Comparison with

Dopamine Receptor Binding, 281

Simantov, Rabi. See Nehmad and Nadler, 389

Slaughter, Shelley R. See Lui, Philpot, and Lucier, 795

Snavely, Marshall D., and Insel, Paul A. Characterization of Alpha-

Adrenergic Receptor Subtypes in the Rat Renal Cortex: Differen-

tial Regulation of Alpha1- and Alpha2-Adrenergic Receptors by

Guanyl Nucleotides and Na�, 532

Snyder, Solomon H. See Murphy, 250

Souccar, Caden. See Maleque, Cohen, and Albuquerque, 636

Squires, Richard F., and Saederup, Else. -y-Aminobutyric Acid

Receptors Modulate Cation Binding Sites Coupled to Independent

Benzodiazepine, Picrotoxin, and Anion Binding Sites, 327

Stadel, Jeffrey M. See Vale, De Lean, and Lefkowitz, 619

Staehlin, Mattys. See Norman, 395

Statham, Charles N. See Wolf, McMenamin, Bend, Boyd, and Phil-

pot, 738

Steele, William J. See Retz, 706

Steinberg, Florence. See Bourne, Beiderman, and Brothers, 204

Steinfelder, Hans-Jurgen. See Joost, 614

Stokes, James A., and Harris, R. Adron. Alcohols and Synaptoso-

mal Calcium Transport, 99

Stump, David C. See Macfarlane, 574

Suen, Erick T., Kwan, Peter C. K., and Clement-Cormier, Yvonne

C. Selective Effects of an Essential Suithydryl Group on the

Activation of Dopamine- and Guanine Nucleotide-Sensitive Ade-

nylate Cyclase, 595

Sufrmn, Janice R., and Lombardini, John B. Differences in the

Active-Site Region of Tumor versus Normal Isozymes of Mars-

malian ATP:L-Methionine S-Adenosyltransferase, 752

Suketa, Yasunobu, Yamada, Masakazu, Hasegawa, Jun, and

Asao, Yukari. A Possible Mechanism for Elevation of Glucose-6-

Phosphatase Activity in Kidney and Liver of Fluoride-Treated

Rats, 116

Swenson, Erik R. See Sanyal, Pessah, and Maren, 211

T

Tachizawa, Haruo, MacDonald, Timothy L., and Neal, Robert A.Rat Liver Microsomal Metabolism of Propyl Halides, 745

Tanaka, Toshio

Ohmura, Takehisa, and Hidaka, Hiroyoshi. Hydrophobic Inter-

action of the Ca2�-Calmodulin Complex with Calmodulin Antago-

fists: Naphthalenesulfonamide Derivatives, 403

Ohmura, Takehisa, Yamakado, Toshiyuki, and Hidaka, Hiro-

yoshi. Two Types of Calcium-Dependent Protein Phosphoryla-

tions Modulated by Calmodulin Antagonists: Naphthalenesulfon-

amide Derivatives, 408

Tank, A. W., and Weiner, N. Induction of Tyrosine Hydroxylase by

Glucocorticoids in Mouse Neuroblastoma Cells: Enhancement of

the Induction by Cyclic AMP, 421

Tattersall, Martin H. N. See Perez, 166

Taylor, John W., Miller, Richard J., and Kaiser, E. T. Structural

Characterization of $-Endorphin through the Design, Synthesis,

and Study of Model Peptides, 657

Taylor, Palmer. See Hughes, Boyle, Brown, and Insel, 258

Thakker, Dhiren R. See Vyas, Levin, Yagi, Ryan, Thomas, Conney,

and Jerina, 182

Thomas, Paul E.

Ryan, Dene E., von Bahr, Christer, Glaumann, Hans, and

Levin, Wayne. Human Liver Microsomal Epoxide Hydrolase:

Correlation oflmmunochemical Quantitation with Catalytic Activ-

ity, 190

See Vya.s, Levin, Yagi, Thakker, Ryan, Conney, and Jerina, 182

Thompson, Wiffiam F.

See Batzri and Harmon, 33

See Batzri, Harmon, and Dyer, 41

Thurman, R. G. See Conway, Kauffman, and Ji, 509

Tice, Arvil J. See Houghton and Houghton, 771

Tolkovsky, A. M. Etorphine Binds to Multiple Opiate Receptors of

the Caudate Nucleus with Equal Affinity but with Different Ki-

netics, 648

Torrens, Y. See Beaujouan, Herbet, Daguet, Glou’inski, and Pro-

chiantz, 48

Trice, Thomas B. See Mottley and Mason, 732

Tukey, Robert H., Negishi, Masahiko, and Nebert, Daniel W.

Quantitation of Hepatic Cytochrome P�-450 with the Use of a

Cloned DNA Probe: Effects of Various P-450 Inducers in C57BL/

6N and DBA/2N Mice, 779

Turner, Chris R. See Keller and Jefcoate, 451

U

Ueng, Tzuu-Huei, and Alvares, Alvito P. Pulmonary Cytochromes

P-450 from Rabbits Treated with 3-Methylcholanthrene, 221

V

Vale, Ronald D., De Lean, Andre, Lefkowitz, Robert J., and

Stadel, Jeffrey M. Regulation of Insulin Receptors in Frog Eryth-

rocytes by Insulin and Concanavalin A: Evidence for Discrete

Classes of Insulin Binding Sites, 619

Vohra, M. M., and Rautanen, P. K. Pharmacological Characteriza-

tion of Histamine Receptors Mediating Cyclic AMP Accumulation

in the Mouse Vas Deferens: Sensitivity to H1 and H2 Receptor

Agonists and Antagonists, 602

Volliner, Karl-Otto. See Quast and Mdhlmann, 20

von Bahr, Christer. See Thomas, Ryan, Glaumann, and Levin, 190

Vyas, Kamlesh P., Levin, Wayne, Yagi, Haruhiko, Thakker,

Dhiren R., Ryan, Dene E., Thomas, Paul E., Conney, Allen

H., and Jerina, Donald M. Stereoselective Metabolism of the

(+)- and (-)-Enantiomers of trans-1,2-Dthydroxy-1,2-Dihydro-

chrysene to Bay-Region 1,2-Diol-3,4-Epoxide Diastereomers by

Rat Liver Enzymes, 182

W

Waelbroeck, M. See Chatelain, Robberecht, De Neef, Camus, and

Christophe, 342

Warnick, Jordan E.

Jessup, Peter J., Overman, Larry E., Eldefrawi, Mohyee E.,

Nimit, Yuth, Daly, John W., and Albuquerque, Edson X.

Pumiiotoxin-C and Synthetic Analogues: A New Class of Nicotinic

Antagonists, 565

Maleque, Mohammed A., Bakry, Nabil, Eldefrawi, Amira T.,

and Albuquerque, Edson X. Structure-Activity Relationships of

Amantadine. I. Interaction of the N-Alkyl Analogues with the

Ionic Channels of the Nicotonic Acetylcholine Receptor and Elec-

trically Excitable Membrane, 82

Weiner, N. See Tank, 421

Williamson, Lenita. See Loew, Hashimoto, Burt, and Anderson, 667

Wiffis, Charles E. See Long, Prestayko, and Crooke, 152

Willow, Max, and Catterall, William A. Inhibition of Binding of

[3H]Batrachotoxinin A 20-a-Benzoate to Sodium Channels by the

Anticonvulsant Drugs Diphenythydantoin and Carbamazepine, 627

Wolf, C. Roland, Statham, Charles N., McMenamin, Mary G.,

Bend, John R., Boyd, Michael R., and Philpot, Richard M.The Relationship between the Catalytic Activities of Rabbit Pul-

monary Cytochrome P-450 Isozymes and the Lung-Specific Tox-

icity of the Furan Derivative, 4-Ipomeanol, 738

Woodcock, Elizabeth A., and Johnston, Colin I. Characterization

of Adenylate Cyclase-Coupled Alpha2-Adrenergic Receptors in

Rat Renal Cortex Using [3H]Yohimbine, 589

W#{252}thrich, Andreas. See Gietzen and Bader, 413

808 AUTHOR INDEX

Y

Yagi, Haruhiko. See Vyas, Levin, Thakker, Ryan, Thomas, Conney,

and Jerina, 182

Yamada, Masakazu. See Suketa, Hasegawa, and Asao, 116

Yamakado, Toshiyuki. See Tanaka, Ohmura, and Hidaka, 408

Yoda, Atsunobu

and Yoda, Shizuko. Formation of ADP-Sensitive Phosphorylated

Intermediate in the Electric Eel Na,K-ATPase Preparation, 693

and Yoda, Shizuko. Interaction between Ouabain and the Phos-

phorylated Intermediate of Na,K-ATPase, 700

Yoda, Shizuko. See Yoda, 693, 700

CUMULATIVE SUBJECT INDEX’ FOR VOLUMES 21 AND 22

809

A

A23187

effect on cyclic AMP, 22, 310

effect on cyclic GMP (guinea pig), 21, 654

Acetaldehyde, effect on membrane fluidity, 22, 721

Acetaniide, interaction with purified liver microsomal isozymes (rab-

bit), 21, 701

4-Acetoxy-4-androstene-3,17-dione, inhibition of estrogen biosynthesis,

21, 173

Acetylcholine

binding, in electroplax membranes (ray), 22, 565

channel noise, 22, 565

interaction with alumina surface, 22, 678

3H-labeledbinding in brain (rat), 22,56

binding to receptor (ray), 22,63

muscarinic analogue, interaction with alumina surface, 22, 678

mcotinic receptor, 21, 351

mcotinic receptor/channel, binding (ray), 22, 63

noise analysis (frog), 22,636

receptor

drug specificity (ray), 22,63

in soleus muscle (rat), 22, 565

ionic channel (frog), 22, 636

ionic channel inactivation (frog), 22, 636

neuromuscular junction (frog), 22, 636

receptor/channel, pharmacology (ray), 22, 72

sensitivity, 22,565

sensitivity (frog), 22, 636

Acetylcholinesterase

edrophonium inhibition (ray), 22,63

inhibition (ray), 22,63

inhibition in Torpedo electric organ, 22,63

N-Acetylglucosaminidase, platelet secretion (human), 21, 422

N-Acetyltransferasecysteine S-conjugate, kidney microsomes (rat), 21, 444

inactivation (hamster), 21, 159

multiplicity (hamster), 21, 159

Aclacinomycin, effect on cytoplasmic RNA in erythroleukemia cells,

22, 152

Acridine derivatives

antileukemic activity, 22, 486

DNA binding, 22, 486

4’-(9-Acridinylamino)methanesulfon-m-anisidide, monosubstituted de-

rivatives, antileukemic activity, 22, 486

Action potential

muscle (frog), 21, 637

skeletal muscle (frog, ray), 22, 82

retardation, 21, 351

Activation, adenylate cyclase, effects ofsulffiydryl groups (dog), 22, 595

Activity

antitumor, 1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187

3-carbomethoxy rifamycin 5, 21, 394

intrinsic, definition in allozyme hypothesis, 22, 580

monooxygenase-like, of tetrameric hemoglobin (rabbit), 21, 1

N-O-Acyltransferase

hepatic (hamster), 21, 159

inactivation (hamster), 21, 159

Addiction, opiate, effects on calmodulin activity (rat), 22, 389

Adenine nucleosides, effects on RNA synthesis, 22, 517

I Boldface numbers indicate appropriate volume; lightface numbers

indicate pagination.

Adenocarcinoma, colon

methotrexate-5-fluorouracil treatment (human), 22, 771

xenografts (human), 22, 771

Adenosine

A,

receptor binding heterogeneity (rat, rabbit, guinea pig, calf, hu-

man), 22, 250

receptor regulation in brain (guinea pig, bovine), 21, 329

antagonism (rat, rabbit, guinea pig, calf, human), 22, 250

effect on glucose transport (rat), 22, 614

effect on insulin receptors (rat), 22, 614

effect on lipid synthesis (rat), 22, 614

modulation of insulin sensitivity (rat), 22, 614

receptor

cation regulation (guinea pig, bovine), 21, 329

guanine nucleotide regulation (guinea pig, bovine), 21, 329

rescue effects in methotrexate-treated cells (human), 21, 718

S-Adenosylhomocysteine

analogues, carboxymethyltransferase inhibition, 21, 181

bindng to hepatocytes (rat), 21, 108

binding to liver plasma membranes (rat), 21, 108

S-Adenosyl-L-methionine, inhibitors of biosynthesis (rat), 22, 752

S-Adenosylmethionine, carboxymethyltransferase inhibition, 21, 181

Adenovirus, RNA synthesis, 22, 517

Adenylate cyclase

activation

by forakolin (human), 21, 680

by forskolin (rat), 22, 109

by forskolin, in lymphoma cells 22, 609

effects of sulihydryl groups (dog), 22, 595

adipocyte, inhibitors, 21, 336

alpha�-adrenergic receptor-coupled, characterization in renal cortex

(rat), 22, 589

alpha inhibition, 21, 17

binding in purified platelet membranes (human), 21, 600

cardiac, thermodependence (rat), 22, 342

compensatory increase, 22, 1

-coupled receptor, anterior pituitary (porcine), 22, 298

coupling proteins, magnesium regulation (mouse), 22, 267

cultured neuroblastoma, 21, 664

dopamine-sensitive (rat), 22, 281

energy of activation (rat), 22, 342

epinephrine inhibition, 22, 574

genetics (mouse), 22, 267, 274

histamine-mediated stimulation in myocardium (human), 21, 671

hormonal inhibition, 21, 336

inhibition, 22, 589

by alpha2-adrenergic receptors (rat), 21, 648

islet cell membrane (rat), 21, 648

La3� inhibition (mouse), 22, 274

lipid incorporation, 21, 492

magnesium regulation (mouse), 22, 267, 274

membrane lipid effects, 22, 360

neuroblastoma cells, opiate inhibition, 21, 483

opiate inhibition, 22, 1

platelet (human), 22, 574

inhibition (human), 21, 609

phenotypes, in 849 lymphoma cells (mouse), 22, 204

receptor coupling, 22, 580

receptor coupling (bovine), 21, 52

receptor coupling (mouse), 22, 204

receptor-mediated inhibition (rat), 21, 570

regulation, 22, 580

renal cortex (rat), 22, 532

810 SUBJECT INDEX

Adenylate cyclase-continuedSc’� inhibition (mouse), 22, 274

stimulation by arachidonic acid metabolites, 21, 664

system, organization (rat), 22, 342

Adipocyte

adenylate cyclase inhibitors, 21, 336

antiipolytic agents, 21, 336

cyclic AMP accumulation (rat), 22, 109

effect of forskolin (rat), 22, 109

effect of hypothyroidism (rat), 22, 109

effect of insulin and adenosine (rat), 22, 614

glucose transport (rat), 22, 614

insulin receptors (rat), 22, 614

lipid synthesis (rat), 22, 614

lipolysis (rat), 22, 109

membrane, adrenergic ligand liposolubiity in (rat), 22, 5

oxytocin action (rat), 22, 381

oxytocin receptor (rat), 22, 381

prostaglandin F42 receptor (hamster), 22, 320

ADP nbosylation, by cholera toxin (mouse), 22, 204

Adrenalectomy, effect on hepatic and renal glucose-6-phosphatase ac-

tivity (rat), 22, 116

Adrenergic ligand

liposolubiity in membranes (rat), 22, 5

n-octanol:water (rat), 22, 5

Adrenergic receptor

alpha-model, 21, 400

role in hepatocyte release of methotrexate (rat), 22, 493

subtype characterization (rat), 22, 532

alpha,-

in submandibular gland (rat), 21, 27

on cloned muscle cell line, coexistence with beta2- (mouse), 22,258

[3H]prazocin (mouse), 22, 258

stimulation in parotid cells (rat), 21, 128

stimulation of phosphatidylinositol-phosphatidic acid turnover

(rat), 21, 128

alpha2-affinity states, 21, 17


binding to adenylate cyclase (rat), 22, 589

conformational requirements, 21, 259

coupling to cyclase, 21, 17

cultured hybrid cells, 21, 17

“down regulation” in platelets (human), 21, 36

inhibition of insulin secretion (rat), 21, 648

in neuroblastoma X glioma cells, 21, 17



platelet membrane and solubilized preparations (human), 21, 609

beta--adenylate cyclase complex (mouse), 22, 267, 274

agonist affmity (mou.w), 22, 204

binding in erythrocyt.es (frog, turkey), 21, 5

binding system (rat), 22,5


interaction with guanine nucleotide binding component (rat), 21,

570

beta2-

[‘251]cyanopindolol (mouse), 22, 258

on cloned muscle cell line, coexistence with alpha,- (mouse), 22,

258

computer modeling, 22, 532

submandibular gland (rat), 21, 27

turnover (mouse), 22, 258

Adriamycin

effect on cytoplasmic RNA in erythroleukemia celLs, 22, 152

hepatic microsomal metabolism (rabbit), 22, 471

molecular associations in aqueous solution, 22, 158

Affinity, agonist, prostaglandin E2 receptors in adipocytes (hamster),

22, 320

Affinity states, dopamine receptors (porcine), 22, 298

Aggregation, stimulus-induced, human platelets, 21, 422

Agonist

acetylcholine receptor, desensitization at neuromuscular junction

(frog), 22, 636

affinity

beta-adrenergic receptors (mouse), 22, 204

prostaglandin E2 receptors in adipocytes (hamster), 22, 320

-antagonist interaction, model, 22, 369

/antagonist two-state binding model, opioid receptor (rat), 22, 349

delta, binding (rat), 21, 564

dopamine, comparison (rat), 21, 114

dopamine receptor, anterior pituitary (porcine), 22, 290

edrophonium (ray), 22, 63

histamine, effect on binding and biological response of gastric mu-

cons! cells (guinea pig), 22, 33

histamine H,, in polymorphonuclear neutrophils (human), 21, 78

histamine H2, in polymorphonuclear neutrophils (human), 21, 78

-induced desensitization, neuromuscular junction (frog), 22, 636

in vivo regulation (chick), 21, 280

mu, binding (rat), 21, 564

muscarinic-induced tremor (rat), 21, 594

opiate, potency and efficacy, 21, 483

platelet alpha2-adrenergic receptor (human), 21, 609

quaternary ammonium (rat), 22, 63

radioligand, binding in neuroblastoma X glioma cells, 21, 17

retained, effect on alpha2-adrenergic receptors in platelets (human),

21, 36

striatal dopamine D-1 receptor, characterization (rat), 22, 281

tetramethylammonium (ray), 22, 63

Albumin, human serum

binding to warfarin, 21, 100

characterization of drug binding area, 21, 387

interaction with cephalosporins, 21, 92

Alcohol, see also Ethanol

effect on free cholesterol transfer in erythrocytes (human), 21, 694

effect on membrane fluidity, 22, 721

dehydrogenase, metabolic compartmentation, 21, 438

neurochemical effects (rat, mouse), 22, 99

Alkaloidopiate, binding in brain (rat), 21, 564

ymca, Ca2�-transport ATPase inhibition (human), 22, 413

N-Alkyl analogues, of amantadine, interaction with mcotinic acetylcho-

line receptor (ray), 22, 82

N-AIkyl compounds, metabolism, 21, 133

Alkyl $-carboline-3-carboxylate binding, brain, thermodynamicchanges (rat), 22, 335

Alkylation, dopamine receptor (bovine), 21, 44

Allosteric interactions in brain (rat), 22, 327

Allozyme hypothesis

definition of intrinsic activity, 22, 580

for receptor function, 22, �8O

Alumina surface, interaction with acetyicholine and ,6-methyl acetyl-

choline, 12, 678

Amantadine, stiucture-activity relationships (ray), 22,82Ames test

for mutagemc potency, 21, 187

1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187

Ametantrone, hepatic microsomal metabolism (rabbit), 22, 471

Amine(s)

aromatic, demethylation, 21, 133

biogenic, storage in intact platelets (human), 22,94lysosomatic, erythrocyte (frog), 22, 619

pump, substrates (rat), 21, 374

Amino acid, a- and N-methyl, conformational analysis (hydra), 21, 629

SUBJECT INDEX 811

in polymorphonuclear neutrophils (human), 21, 78

long-acting (rat, guinea pig), 21, 294

-y-Aminobutyric acid

benzodiazepine receptor regulation (mouse), 21, 618

effect on benzodiazepine binding (rat), 22, 26

effect on [3Hjdiazepam binding (rat), 22, 26

effect on [3H]flumtrazepam binding (rat), 21, 57

-ionophore complex, 21, 320

mimetics, in brain (rat), 22, 327

modulation (rat), 22, 335

receptor, modulation of cation binding sites (rat), 22, 327

p-Aminoclonidine, 3H-labeled

alpha2-adrenergic receptors, 21, 17


5’-Amino-5’-deoxythymidine, inhibition of thymidine kinase, 22, 231

2-Amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, effect on dopa-

mine synthesis (rat), 21, 114

6-Aminolevulinic acid, synthase, effect on organometals (rat), 21, 150

Aminotransferase, tyrosine, hepatic, effect of pregnenolone-16a-carbo-

nitrile (rat), 21, 753

Ammonium

quaternary, agonists and antagonists (ray), 22, 63

quaternary drugs, interactions in Torpedo electric organ, 22, 63

Amphiphiic helices, /1-endorphin, 22, 657

Analgesia

narcotic, 21, 548

opiate (rat), 21, 272

Analogue

acetylcholine, interaction with alumina surface, 22, 678

S-adenosylhomocysteine, 21, 181

binding in liver (rat), 21, 108

N-alkyl, of amantadine, interaction with nicotinic acetylcholine re-

ceptor (ray), 22, 82

clonidine, crystallographic and quantum mechanical analysis, 21,400

folic acid, release from hepatocytes (rat), 22, 493

-y-glutamylcysteinylglycine (hydra), 21, 629

L-methionine, substrate and inhibitory properties (rat), 22, 752

methotrexate, 21, 231

norfenfluramine, conformationally defined, 22, 127

oxytocin, action in adipocytes (rat), 22, 381

phencyclidine (frog), 21, 637

phencyclidine, binding to acetylcholine receptor (ray), 22, 72

phenylethylamines, conformationally defined, 22, 127

synthetic, pumiiotoxin-C, 22, 565

Anesthetic

interaction with benzodiazepine receptors, 21, 320

mechanisms, 22, 133

1-Aniinonaphthalene-8-sulfonic acid, in study of membrane fluidity,

22, 721

Anion

binding sites in brain (rat), 22, 327

inhibition of skeletal muscle carbonic anhydrase (cat), 22, 211

recognition sites in brain (rat), 21, 327

sulfur trioxide radical, direct detection during oxidation of sulfite, 22,

732

Ansamycins, structure-activity relationships, 21, 394

Antagonism, uncompetitive, 22, 369

Antagonistadenosine (rat, rabbit, guinea pig, calf, human), 22, 250

-agonist interaction, model, 22, 369

/agonist two-state binding model, opioid receptor (rat), 22, 349

binding, cooperativity studies (rat), 21, 287

cahnodulin

interaction with Ca2�-ca1modulin complex, 22, 403

phosphorylation modulation, 22, 408

dopamine receptor, anterior pituitary (porcine), 22, 290

edrophonium (ray), 22, 63

histamine H,

histamine H2

effect on binding and biological response of gastric mucosal cells

(guinea pig), 22, 41


nicotinic, binding, 22, 565

platelet alpha2-adrenergic receptor (human), 21, 609

radioligand binding in neuroblastoma x glioma cells, 21, 17

regulatory site, 22, 231

quatemary ammonium (ray), 22, 63

Anthracenedione, inhibition of microsomal oxidative drug metabolism

(rabbit), 22, 471

Anthracycline

analogues, cytotoxicity, 22, 152

antitumor effects, 21, 196

effect on cytoplasmic RNA in erythroleukemia cells, 22, 152

inhibition of microsomal oxidative drug metabolism (rabbit), 22, 471

molecular associations, 22, 158

Antiarrhythmic drugs, inhibition of phencyclidine binding (ray), 22, 72

Antibody, monoclonal

distinction of monoamine oxidase A and B, 22, 500

to cytochrome P-45OLM2 and P-45O,�M4, 21, 248

Antibiotics

binding to acetylcholine receptor (ray), 22, 72

inhibition of phencyclidine binding (ray), 22, 72

Anticonvulsant property

a-substituted -y-butyrolactones (mouse, guinea pig), 22, 438

a,-y-substituted y-butyrolactones (mouse, guinea pig), 22, 438

-y-substituted y-butyrolactones (mouse, guinea pig), 22, 438

Anticonvulsantseffect on batrachotoxin binding, 22, 627

interaction with benzodiazepine receptors, 21, 320

Antidepressant drugs, inhibition of phencyclidine binding (ray), 22, 72

Antidepressants, tricyclic, interaction with phencyclidine (ray), 22, 72

Antiestrogen, interaction with muscarinic receptors (rat), 21, 287

Antiherpes, selective agents, 21, 217

Anti-inflammatory drugs

metabolism by neutrophils (rat), 21, 688

nonsteroidal, structure-activity relationships, 22, 525

Antileukemic activity, monosubstituted derivatives of 4’-(9-acndinyl-

amino)methanesulfon-m-anisidide, 22, 486

Antiipolytic agents, adipocyte, 21, 336

Antimalarial agents, lipophilic chelators, 22, 140

Antimetabolic activity, 5-substituted 2’-deoxycytidines, 21, 217

Antimetabolite, antineoplastic, 21, 224

Antineoplastic agent

drug synergism, 21, 224

microsomal inhibition (rabbit), 22, 471

Antinucleoside, immunoreactivity (mouse), 21, 739

Antipsychotic drugs


inhibition of phencyclidine binding (ray), 22, 72

I Antipsychotics, tricyclic, mitochondrial ATPase inhibition (bovine), 21,

415

Antitumor activity

monosubstituted derivatives, 4’-(9-acridinylamino)methanesulfon-m-

anisidide, 22, 486

1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187

Antitumor effects, of anthracyclines, 21, 196

Antiviral activity, 5-substituted 2’-deoxycytidines, 21, 217

Antiviral drugs

effect on nicotinic acetylcholine receptor (frog, ray), 22, 82

inhibition of phencycidine binding (ray), 22, 72

Anxiolytic drug, quantitative structure-activity relationships, 22, 11

Aorta, surgical stenosis, effect on cardiac muscarinic receptors (rat), 21,

589

Apomorphine

effect on dopamine synthesis (rat), 21, 114

‘H-labeled, dopamine receptor binding (bovine), 21, 44, 52

812 SUBJECT INDEX

9-fl-D-Arabinofuranosyladenine, inhibition of RNA polyadenylation,

22, 517

9-$-D-Arabinofuranosyl-2-fluoroadenine, cytotoxicity, 21, 474

Arachidonic acid

metabolism by neutrophils (rat), 21, 688

metabolites, stimulation of neuroblastoma adenylate cyclase, 21, 664

Aroclor 1254

aryl hydrocarbon hydroxylase induction (rat), 21, 239

7-ethoxycoumarin deethylase induction (rat), 21, 239

Aromataseenzyme catalysis, 21, 173

inhibition, 21, 173

suicide substrates, 21, 173

Aromatic compound, molecular association with Adriamycin, 22, 158

Arylamide N-hydroxylase, liver, modification (rat), 21, 449

Aryl hydrocarbon hydroxylase

Aroclor induction (rat), 21, 239

benzo[a]pyrene oxygenation, 21, 248

microsomal activity (mouse), 22, 779

Arylhydroxamic acid

bioactivation (hamster), 21, 159

suicide inhibitors (hamster), 21, 159

Aspartate transcarbamylase, inhibition, 21, 224

Assay, fluorescence, for cellular DNA damage, 22, 145

Astemizole, binding characteristics (rat, guinea pig), 21, 294

Astrocytoma cellmuscarinic cholinergic receptor (human), 22, 310

phosphodiesterase activity (human), 22, 310

ATP

:L-methiornne S-adenosyltransferase, differences in active-site region

(rat), 22, 752

platelet secretion (human), 21, 422

ATPase

(Ca21, cardiac sarcoplasmic reticulum, effect of halothane (bovine),

22, 8

Ca2�-transport

calmodulin-dependent (human), 22, 413

vinblastine inhibition (human), 22, 413

heart mitochondrial, fluphenazine inhibition (bovine), 21, 415

Atropine, binding in heart (rat), 21, 581

Autonomic receptor, in submandibular gland (rat), 21, 27

Azapropazone, high-affinity binding sites, 21, 387

Aziridinium ions, inhibition of norepinephrine uptake, 21, 380

B

Bacteria, cell wall, penetration by rifamycins, 21, 394

Barbiturates, interaction with benzodiazepine receptors, 21, 320

Batrachotoxin, binding to sodium channels, 22, 627

Bay-region diol epoxide, stereoselective metabolism (rat), 22, 182

BC3H-1, cloned muscle cell line (mouse), 22, 258

Benzo[a]anthracene, induction of cytochrome P-450 (mouse), 22, 779

Benzodiazepine

binding, brain, thermodynamic changes (rat), 22, 335

binding sites

y-aminobutyric acid receptor, modulation (rat), 22, 327

distance geometry analysis, 22, 11

peripheral-type, characterization (rat), 22, 26

pharmacophore, 22, 11

receptor

y-aminobutyric acid regulation (mouse), 21, 618

chloride channel regulation (mouse), 21, 618

heterogeneity (mouse), 21, 618

in brain (rat), 22, 327

ion regulation (mouse), 21, 618

interaction, temperature dependence (rat), 22, 20

interaction with barbiturates, 21, 320

membrane (rat), 21, 57

photoaffinity labeling (mouse), 21, 618

thermodynamics of binding (rat), 22, 20

Benzo[a]pyrene

hydroxylation, 21, 248

metabolism, 21, 248

metabolism (fish), 21, 517

metabolism, kinetic determinants (rat), 22, 451

Benzyl hydrodisufflde, inhibition of liver cytochrome P-450 (rat), 21,

464

Binding

acetylcholine, in electroplax membranes (ray), 22, 565

acridine derivatives, by DNA, 22, 486

adenosine A, receptors, species heterogeneity (rat, rabbit, guinea pig,

calf, human), 22, 250

S-adenosylhomocysteine, in liver (rat), 21, 108

alkyl /?-carboline-3-carboxylate, brain, thermodynamic changes (rat),

22, 335

antiestrogen (rat), 21, 287

batrachotoxin, inhibition 22, 627

benzodiazepinebrain, thermodynamic changes (rat), 22, 335

characterization of peripheral-type sites (rat), 22, 26

thermodynamics (rat), 22, 20

beta-adrenergic system (rat), 22, 5

a-bungarotoxin, in brain (mouse), 22, 554

carbamylcholine, in electroplax membranes (ray), 22, 565

cation, to glucagon, 22, 105

delta agonist (rat), 21, 564

DNA, correlation with anthracycline antitumor potency, 21, 196

[3H]dopamine, caudate nucleus (calf), 22, 281

dopamine D-1 receptor, characterization (rat), 22, 281

enthalpy, brain homogenates (rat), 22, 335

enthalpy-driven (rat), 22, 20

entropy, brain homogenates (rat), 22, 335

entropy-driven (rat), 22, 20

equilibrium, [3H]diazepam, 21, 320

etorphine, opiate receptors of caudate nucleus (sheep), 22, 648

[3H]etorphine

in vitro, 21, 548

receptor in vivo (rat), 21, 272

gastric mucosal cells

effect of histamine agonists (guinea pig), 22, 33

effect of histamine H2 antagonists (guinea pig), 22, 41

GTP regulatory protein (bovine), 21, 52

in vitro, characteristics, 21, 294

in vivo, characteristics (rat, guinea pig), 21, 294

[3H}ketanserin (rat), 21, 301

kinetics

association and dissociation (rat), 21, 57

human serum albumin, 21, 100

[3H]leucine enkephalin

effect of morphine (rat), 21, 538

in vitro, 21, 548

ligand, 21, 558

3H-ligand, effect of heat treatment (bovine), 21, 52

long-acting H1 antagonist (rat, guinea pig), 21, 294

mu agonist (rat), 21, 564

muscarinic receptor

aceclidine and its methiodide (rat), 21, 594


nicotine, in brain (mouse), 22, 554

nicotinic acetylcholine receptor/channel (ray), 22, 63

nonspecific, saxitoxin, 21, 343

opiate receptor, 21, 483, 492


opioid receptor, two-state model (rat), 22, 349

ouabain, to digitalis receptor (rat, guinea pig), 22, 687

[3H}n-propylapomorphine, in pituitary (porcine), 22, 290, 298

protein, human serum albumin, 21, 100

SUBJECT INDEX 813

quinucidinyl benzilate, in brain (mouse), 22, 554

radioligand

computer modeling, 21, 5


receptor

$-endorphin models, 22, 657

guanine nucleotide regulation (hamster), 22, 320

monovalent cations (hamster), 22, 320

site

anion, in brain (rat), 22, 327

benzodiazepine, distance geometry analysis, 22, 11

benzodiazepine, in brain (rat), 22, 327

cardiac, effects of guanine nucleotides (rat), 21, 581

cation, y-aminobutyric acid modulation (rat), 22, 327

characterization, 21, 387

high-affinity, azapropazone, 21, 387

high-affinity, warfarin, 21,387insulin, in erythrocytes (frog), 22, 619

opiates, 21, 266

picrotoxin, in brain (rat), 22, 327

saxitoxin, structure, 21, 343

sodium channels in nerve membranes, 21, 343

spiperone, in brain (rat), 22, 243

[3H]spiroperidol

caudate nucleus (calf), 22, 281

pituitary (porcine), 22, 290, 298

substance P derivative, to mesencephalic cells (mouse), 22, 48

toxin molecules, exchange of tritium, 21, 343

two-site model (cat), 22, 304

zinc, to glucagon, 22, 105

Biogenic amines, storage in intact platelets (human), 22, 94

Biosynthesis

estrogen, inhibition, 21, 173

prostaglandin, N-alkylation during, 21, 133

Bisbenzamide, assay for cellular DNA damage, 22, 145

1,4-Bis(2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione

diacetate, inhibition of microsomal oxidative drug metabolism

(rabbit), 22, 471

Bladder, urinary, water flow (toad), 21, 142

Blood platelets, storage of biogenic amines (human), 22, 94

Blot hybridizationDNA (mouse), 22, 779

mRNA (mouse), 22, 779

Brain

[3Hjacetylcholine binding sites (rat), 22, 56

adenosine A, receptor binding, species heterogeneity (rat, rabbit,

guinea pig, calf, human), 22, 250

adenylate cyclase, effects of sulhydryl groups (dog), 22, 595

alkyl fl-carboline-3-carboxylate binding (rat), 22, 335

y-aminobutyric acid receptors (rat), 22, 327

ATP concentration, effect of morphine (rat), 22, 706

benzodiazepine

binding (rat), 22, 335

binding, characterization of peripheral-type sites (rat), 22, 26

receptors (mouse), 21, 618

receptors (rat), 22, 327

digitalis receptor, inhibition of ouabain binding (rat), 22, 687

effects of morphine treatment on calmodulin activity (rat), 22, 389

embryonic, muscarinic receptors (chick), 21, 280

[3H]ketanserin distribution (rat), 21, 301

membrane, opiate binding (rat), 21, 564

nicotinic cholinergic receptors (rat), 22, 56

particulate fraction, [‘H]leucine enkephalin binding (rat), 21, 538

protein synthesis inhibition by morphine (rat), 22, 706

serotonin receptors, characterization (rat), 22, 243

spiperone binding (rat), 22, 243

5-Bromo-2’-deoxycytidine, antiherpes activity, 21, 217

(E)-5-(2-Bromovinyl)-2’-deoxycytidine, antiviral and antimetabolic

properties, 21, 217

(E)-5-(2-Bromovinyl)-2’-deoxyuridine

differential antiviral activity, 21, 432

phosphorylation, 21, 432

a-Bungarotoxin

binding in brain (mouse), 22, 554

receptor, binding in brain (mouse), 22, 554

y-Butyrolactone

alkyl-substituted, structure-activity relationships (mouse, guinea

pig), 22, 444

a-substituted, anticonvulsant properties (mouse, guinea pig), 22, 438

a,y-substituted, anticonvulsant properties (mouse, guinea pig), 22,

438

$-alkyl-substituted, eleptogenic properties (mouse, guinea pig), 22,

431

-y-substituted, anticonvulsant properties (mouse, guinea pig), 22, 438

unsubstituted, eleptogenic properties (mouse, guinea pig), 22, 431

C

Ca2�, see also Calcium

-ATPase, cardiac sarcoplasmic reticulum, effect of halothane (bo-

vine), 22, 8

-calmodulin-dependent phosphorylation, 22, 408

-calmodulin complex, interaction with calmodulin antagonists, 22,

403

-H� exchange diffusion (mouse), 22, 715

ionophore


hypoglycemic sulfonylureas (mouse), 22, 715

phospholipid-dependent phosphorylation, 22, 408

-transport ATPase, calmodulin-dependent (human), 22, 413

Cadmium-sensitive hepatic cytochrome P-450 (rat), 22, 795

Calcium, see also Ca2�

effect of halothane at low concentrations (bovine), 22, 8

platelet secretion (human), 21, 422

stimulus-induced mobilization in human platelets, 21, 422

transport

in excitable cells (mouse), 22, 715

in isolated secretory granules (mouse), 22, 715

uptake

glutamate-stimulated (rat, mouse), 22, 99

potassium-stimulated (rat, mouse), 22, 99

synaptosomal (rat, mouse), 22, 99

Calmodulin

antagonist

effect on human platelets, 21, 422

interaction with Ca2�-calmodulin complex, 22, 403

phosphorylation modulation, 22, 408

-Ca2� complex, interaction with calmodulin antagonists, 22, 403

effects of morphine treatment (rat), 22, 389

-dependent Ca2�-transport ATPase (human), 22, 413

human platelet, effect of trifluoperazine, 21, 422

inhibition (bovine), 21, 86

inhibitors, in C6 glioma cells, 22, 395

vinblastine binding (human), 22, 413

Carbachol

cyclic GMP stimulation (guinea pig), 21, 654

effect on cultured thyroid cells (porcine), 21, 66, 73

fatty acid hydroperoxides, cyclic GMP (guinea pig), 21, 654

-induced desensitization, cultured thyroid cells (porcine), 21, 73

phospholipase A2 stimulation (guinea pig), 21, 654

Carbamazepine, effect on batrachotoxin binding, 22, 627

Carbamoylation, in nitrosourea cytotoxicity (rat), 21, 729

Carbamylcholine binding

in electroplax membranes (ray), 22, 565

in heart (rat), 21, 581

Carbomethoxy, stereospecificity at position 10, 21, 196

lethality

5-fluorouracil (human), 21, 468

5-fluorouridine (human), 21, 468

leukemia, hypoxic, synergistic toxicity of misomdazole and sulfido-

cyclophosphamide (mouse), 22, 175

lymphoblast, deoxyuridine metabolism (human), 22, 166

mesencephalic, substance P derivative binding (mouse), 22, 48

methotrexate-treated, 21, 204

rescue effects of folinic acid and glycine, adenosine, and thymidine

(human), 21, 718

morphological transformation (mouse), 21, 739

muscle, cloned, BC3H-l (mouse), 22, 258

neuroblastoma

serotonin uptake, 21, 362

tyrosine hydroxylase induction (mouse), 22, 421

neuroblastoma N18TG2


potentiation of opiate action, 21, 492

neuroblastoma x glioma hybrid, adenylate cyclase activity, 22, 360

neuroblastoma x glioma NG1O8-15 hybrid


opiate receptor activity, 22, 1

neuronal, culture (mouse), 22, 48

parotid, phosphatidylinositol-phosphatidic acid turnover (rat), 21,

128

3-Carbomethoxy rifamycin 5, molecular structure by ‘H NMR and X-

rays, 21, 394

Carbon-centered free radical (rat), 22, 239

Carbon dioxide, hydration activity of skeletal muscle (cat), 22, 211

Carbonic anhydrase, skeletal muscle, carbon dioxide hydration activity

(cat), 22, 211

Carboxymethyltransferase, synaptosomal, inhibition (calf, rat), 21, 181

Carcinogen, chemical, phenacetin, 22, 479

Carcinogenesis, role of bay-region diol epoxide (rat), 22, 182

Carcinogenicity, polycyclic aromatic hydrocarbons, 22, 459

Carcinoma

colon, cultured cells (human), 21, 468

selective cytotoxicity of haloethylnitrosoureas (rat), 21, 729

Walker 256 (rat), 21, 729

Cardiotoxicity, anthracycline antineoplastic agents, 22, 471

Carminomycin, effect on cytoplasmic RNA in erythroleukemia cells,

22, 152

Catalysis, aromatase enzyme, 21, 173

Catalytic activity

liver microsomal epoxide hydrolase (human), 22, 190

pulmonary cytochrome P-450 isozymes (rabbit), 22, 738

Catecholamine

effect on adenylate cyclase in myocardium (human), 21, 671

effect on binding in platelets (human), 21, 609

effect on binding in purified platelet membranes (human), 21, 600

effect on ion fluxes in erythrocytes (turkey), 21, 503

-induced release of methotrexate from hepatocytes (rat), 22, 493

receptor, binding in erythrocytes (frog, turkey), 21, 5

Cation

binding, glucagon, 22, 105

binding sites, y-aminobutyric acid modulation (rat), 22, 327

fluxes, in erythrocytes (turkey), 21, 503

monovalent

effect on binding in platelets (human), 21, 609


effect on prostaglandin E2 receptors in adipocytes (hamster), 22,

320

receptor regulation (guinea pig, bovine), 21, 329

recognition sites in brain (rat), 22, 327

Caudate membrane, 3H-ligand binding sites (bovine), 21, 44, 52

Caudate nucleus, opiate receptors, etorphine binding (sheep), 22, 648

Cellantinucleoside immunoreactivity (mouse), 21, 739

astrocytoma

muscarinic cholinergic receptor (human), 22, 310

phosphodiesterase activity (human), 22, 310

carcinoma

in culture (human), 21, 468

resistance to bifunctional nitrogen mustards (rat), 21, 729

selective toxicity of haloethylnitrosoureas (rat), 21, 729

culture, L1210 leukemia, 22, 486

cycle, effect of methotrexate, 21, 204

cytochrome P-450, effect of organometals (rat), 21, 150

differentiation (human), 22, 547

DNAfluorescence assay for damage, 22, 145

strand separation (mouse), 21, 739

erythroleukemia, RNA transport, 22, 152

excitable, calcium transport (mouse), 22, 715

gastric mucosa, interaction with histamine (guinea pig), 22, 33, 41

glioma C6

calmodulin inhibitors, 22, 395

glycogen phosphorylase conversion B to A, 22, 395

HeLa, 9-$-D-arabinofuranosyl-2-fluoroadenine inhibition (human),

21, 474

KB

dihydrofolate reduct.ase (human), 21, 231

methotrexate-resistant (human), 21, 231, 248


proliferation (human), 22, 547

promyelocytic leukemia HL-60 (human), 22, 547

5180 AT/3000, dihydrofolate reductase (mouse), 21, 231

549 lymphoma, adenylate cyclase phenotypes (mouse), 22, 204

thyroid

culture (porcine), 21, 66, 73

muscarinic cholinergic receptors on (porcine), 21, 66, 73

Central nervous system

depressant drugs, 21, 320

receptors, in vitro, 21, 315

substance P binding (mouse), 22, 48

Cephalosporin, interaction with human serum albumin, 21, 92

Cerebroside sulfate, acidic lipids, 21, 492

CF 25-397, see 9, l0-Didehydro-6-methyl-3$- (2-pyridylthiomethyl)-

ergoline

Channel noise, acetylcholine, 22, 565

Chelator, lipophiic, antimalarial activity, 22, 140

CHEMLAB, triazene mutagenicity analysis, 21, 187

Chemotherapy, drug design, 22, 231

Chioramphenicol, cytochrome P-450 inactivation (rat), 21, 166

Chloride channel, benzodiazepine receptor regulation (mouse), 21, 618

N-2’-Chloroethyl-N-ethyl-2-methylbenzylamine, chemical transforma-

tions in solution, 21, 380

N-2’-Chloroethyl-2-methylbenzylamine, inhibition of norepinephrine

uptake, 21, 380

1-Chloro-2,2,2-trifluoroethyl radical, binding to phospholipids (human,

rabbit), 21, 710

Chlorpromazine, ring sulfoxidation, 21, 409

Cholera toxin

ADP ribosylation (mouse), 22, 204

effect on cardiac adenylate cyclase activity (rat), 22, 342

Cholesterol, free, transfer into erythrocytes (human), 21, 694

Cholic acid, sodium salt, effect on opiate binding (rat), 21, 564

Cholinergic receptor

muscarinic (mouse), 22, 554

nicotinic (mouse), 22, 554

Chromaffin granules, calcium transport (mouse), 22, 715

Chromatin, thymus

formaldehyde cross-linking (calf), 22, 121

methylmercury complexes (calf), 22, 121

814 SUBJECT INDEX

pheochromocytoma

norepinephrine uptake, 21, 368

SUBJECT INDEX 815

L1210 leukemia cells, 22, 486

Lymphoblasts, deoxyuridine metabolism (human), 22, 166

Chromatography

column, pulmonary cytochrome P-450 (rabbit), 22, 221

high-pressure liquid, benzo[a]pyrene metabolism, 21, 248

Chromosomemarkers, in nitrosourea cytotoxicity (rat), 21, 729

modal number (rat), 21, 729

Chrysene 1,2-dihydriols, stereoselective metabolism (rat), 22, 182

Circular dichroism, glucagon, 22, 105

Clomiphene, interaction with muscarinic receptors (rat), 21, 287

ClonecDNA, for P,-450 (mouse), 22, 779

muscle cell line, BC3H-1 (mouse), 22, 258

neuroblastoma variants, characterization, 22, 196

Clonidine, pharmacology, 21, 400

Cocaine metabolite, hepatotoxicity (rat, hamster), 21, 458

Colchicine, effect on urinary bladder (toad), 21, 142

Colon

adenocarcinoma

methotrexate-5-fluorouracil treatment (human), 22, 771

xenografts (human), 22, 771

carcinoma, cultured cells (human), 21, 468

xenografts, selectivity (human), 22, 7711

Complex

cephalosporin-human serum albumin, 21,92

metabolic-intermediate, cytochrome P-450, from isosafrole (rat), 21,

527

Computer modeling

adrenergic receptors, 22, 532

for radioligand binding data, 21, 5

Computerized curve-fitting technique, discrimination ofopiate receptor

binding sites, 21, 266

Concanavalin A, regulation of insulin receptors in erythrocytes (frog),

22, 619

Conformation

-energy calculations, 22, 667

interconvertible, benzodiazepine receptor (rat), 21, 57

sodium channel, 21,343

Conformational analysis

a- and N-methyl amino acids (hydra), 21,629

l-(Lphenyl)-3,3-dialkyltriazenes, 21, 187

Conformational change, glucagon, 22, 105

Conformational model, two-state, for phenylethanolamine N-methyl-

transferase, 22, 127

Conformational preference, phenylethanolamine N-methyltransferase

substrates, 22, 127

Conformational requirements, alpha2-adrenergic receptors, 21, 259

Conformer, active/inactive, 22, 667

Constant, high metal binding, oxine, 22, 140

Cooperativity

antiestrogen with muscarinic receptors (rat), 21, 287

lipid transition, 22, 133

Co-oxidation, prostaglandin synthetase, 21, 133

Correlation, dopamine-sensitive adenylate cyclase/[’H]dopamine bind-

ing, 22, 281

Cortex, cerebral, synaptosomal membranes (rat), 21, 57

Coupling

collision, bidirectional, to adenylate cyclase, 22, 580

factor, definition, 22, 580

receptors to adenylate cyclase, 22, 580

Cross-reaction minimalization, opiate alkaloid and peptide, by man-

ganese (rat), 21, 564

Crystallographic analysis, clonidine, 21, 400

Culturecarcinoma cells (human), 21, 468

L1210 cells, cytotoxicity of 5-fluoro-5’-O-nitro-2’-deoxyuridine, 22,

760

neuroblastoma cells

adenylate cyclase, 21, 664


neuronal cells (mouse), 22, 48

pheochromocytoma cells



primary, mesencephalic cells (mouse), 22, 48

Current, end-plate

amplitude, 22, 565

decay, 22, 565

Curve-fitting technique, computerized, discrimination of opiate recep-

tor binding sites, 21, 266

Cyanopindolol, 3H-labeled, beta2-adrenergic receptor (mouse), 22, 258

Cyclic AMP

accumulation in adipocytes (rat), 22, 109

accumulation in lymphoma cells, 22, 609

accumulation in van deferens (mouse), 22, 602

degradation in astrocytoma cells (human), 22, 310

enhancement of tyrosine hydroxylase induction (mouse), 22, 421

forskolin activation (rat), 22, 109

generation in pancreatic islets (rat), 21, 648

in promyelocytic leukemia cells (human), 22, 547

levels in cultured thyroid cells (porcine), 21, 66

myocardial (human), 21, 671

neuroblastoma cell (mouse), 22, 421

platelet levels (human), 21, 680

inhibition by forskolin, 21, 680

polymorphonuclear neutrophils (human), 21, 78

protein kinase (rat), 21, 121

receptors, in erythrocytes (turkey), 21, 503

Cyclic GMP, carbachol stimulatory effect (guinea pig), 21, 654

Cyclohexyladenosine, 3H-labeled, binding to adenosine A, receptors in

brain (guinea pig, bovine), 21, 329

Cyclooxygenase, metabolism of arachidonic acid by neutrophils (rat),

21, 688

Cysteine, S-conjugate N-acetyltransferase, kidney microsomes (rat),

21,444

Cytochrome

b5, substrate interaction (rabbit), 21, 701

P-450

cardiac microsomes (fish), 21, 517

cellular, effect of organometals (rat), 21, 150

content in neonatal skin (rat), 21, 239

effects of cadmium (rat), 22, 795

electrophoresis, 22, 787

‘H Fourier transform studies (rabbit), 21, 701

H2O2 generation by hydroxylamines (rat), 22, 465

hepatic, alkyl halide metabolism (rat), 22, 745

hepatic, cadmium-sensitive (rat), 22, 795

hepatic, immunochemistry (rat), 21, 753

hepatic, inactivation (rat), 21, 166

hepatic, induction with pregnenolone-16a-carbonitrile (rat), 21,

753

hepatic, neonatal imprinting and (rat), 21, 744

hepatic, neonatally imprinted forms (rat), 21, 744

hepatic, opposing effects of N-hydroxyamphetamine and N-hy-

droxyphentermine (rat), 22, 465

hepatic, reconstituted (rabbit), 22, 235

hepatic, reduction of gentian violet (rat), 22, 239

hepatic, sex-dependent forms (rat), 21, 744

hepatic, stereoselective metabolism (rat), 22, 182

hepatic, turnover (rat), 21, 744

immunochemical studies (rat), 21, 744

induction, genetic differences (mouse), 22, 779

inhibition by benzyl hydrodisulfide (rat), 21, 464

metabolic-intermediate complexes from isosafrole (rat), 21, 527

microsomal, of skin, dermis, and epidermis (rat), 21, 239

816 SUBJECT INDEX

Cytochrome-continued

P-450-continued

multiple forms (rat), 22, 795

NADPH reductase, hepatic microsomal (rabbit), 22, 471

N-oxidation of phentermine (rabbit), 22, 235

pulmonary, isozymes (rabbit), 22, 738

pulmonary, 3-methylcholanthrene induction (rabbit), 22, 221

pulmonary, multiple forms (rabbit), 22, 221

pulmonary, role in toxicity of 4-ipomeanol (rabbit), 22, 738

pulmonary, spectral and electrophoretic properties (rabbit), 22,

221

radical formation (rat), 22, 239

reductive metabolism of halothane (human, rabbit), 21, 710

sex differentiation (rat), 22, 795

subpopulations, induction by isosafrole (rat), 21, 527

subpopulations, induction by /3-naphthoflavone (rat), 21, 527

subpopulations, induction by phenobarbit.al (rat), 21, 527

substrate interaction (rabbit), 21, 701

P-450,,,, 3-methylcholanthrene induction (rabbit), 22, 221

P-45OLM2, monoclonal antibodies to, 21, 248

P-45OLM4, monoclonal antibodies to, 21, 248

P,-450

messenger RNA (mouse), 22, 779

protein (mouse), 22, 779

Cytometry, flow, deoxyuridine treatment in lymphoblasts (human), 22,

166

Cytoplasm, RNA, effect of anthracyclines, 22, 152

Cytotoxicity, see also Toxicity

anthracycline analogues, 22, 152

deoxyuridine (human), 22, 166

5-fluorodeoxyuridine, 21, 211

in gastrointestinal tumor (human), 21, 723

5-fluoro-5’-O-nitro-2’-deoxyuridine, in L1210 cultures, 22, 760

methotrexate, 21, 204

methotrexate (human), 21, 718

in gastrointestinal tumor, 21, 723

misonidazole (mouse), 22, 175

selective, haloethylnitrosoureas in carcinoma (rat), 21, 729

5-substituted 2’-deoxycytidines, 21, 217

D

Daunomycin, effect on cytoplasmic RNA in erythroleukemia cells, 22,

152

Deactivating system, basal, postulated, 22, 580

Decomposition, superoxide spin-trapped adducts, 21, 262

Dehydrogenase, alcohol, metabolic compartmentation, 21,438

Dehydrogenase, NADH, hepatic microsomal (rabbit), 22, 471

De novo constants, correlations between, 22, 725

Depressant drugs, interaction with benzodiazepine receptors, 21, 320

3’-Deoxyadenosine, effect on RNA synthesis, 22, 517

2’-Deoxycytidines, 5-substituted, antiviral, antimetabolic, and cytotoxic

activities, 21, 217

Deoxyuridine

cytotoxicity (human), 22, 166

phosphates, cytosol, 21, 224

4-Demethoxydaunomycin, effect on cytoplasmic RNA in erythroleu-

kemia cells, 22, 152

Desensitization

cultured thyroid cells (porcine), 21, 73


Desmethylimipramineinhibition of norepinephrine uptake, 21, 368

inhibition of serotonin uptake, 21, 362, 368

Dexamethasone, induction of hepatic cytochrome P-450 (rat), 21, 753

Dexetimide, inhibition of binding in heart (rat), 21, 581

Dialysis, equilibrium, cephalosporin-human serum albumin complexes,

21, 92

2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-djpyrimi-

dine, metabolic inhibition (mouse), 22, 766

Diarachidonyl diglyceride, formation by neutrophils (rat), 21, 688

Diazepam, ‘H-labeled, equilibrium binding, 21, 320

9,10-Didehydro-6-methyl-3$-(2-pyridylthiomethyl)ergoline, effect on

dopamine synthesis (rat), 21, 114

fl-Diethylaminoethyl-2,2-diphenylpentanoate, translocation of estrogen

receptor (rat), 21, 533

Diethylphenylxanthine, ‘H-labeled, binding to adenosine A, receptors

in brain (guinea pig, bovine), 21, 329

Differentiation, cellular (human), 22, 547

Digitalis receptor, light-enhanced inhibition ofbinding (rat, guinea pig),

22, 687

Diglyceride, diarachidonyl, formation by neutrophuls (rat), 21, 688

Dihydriol epoxide, formation in liver (rat), 22, 451

Dihydroalprenolol, 3H-labeled

adipocyte membranes (rat), 22, 5

binding in erythrocytes (frog, turkey), 21, 5

Dihydrofolate reductase

effect of methotrexate (human), 21, 478

in human KB cells, 21, 231

mouse cell lines, inhibition by antilolate BW3O1U, 22, 766

Dihydromorphine, ‘H-labeled, binding in brain (rat), 22, 349

Dihydroxyaminotetralins, effect on dopamine receptor binding (rat),

22, 281

3,4-Dihydroxyphenylamino-2-jmidazoline, effect on dopamine synthe-

sis (rat), 21, 114

5,6-Dihydroxytryptamine, cytotoxic effect, 21, 362, 368

5,7-Dihydroxytryptamine, cytotoxic effect, 21, 362, 368

Dimer, enkephalin, affinity and selectivity for delta opiate receptor, 21,

558

Dimethylaniline N-oxidase, quantitation, 22, 787

Diol epoxide, bay-region, stereoselective metabolism (rat), 22, 182

Dipalmitoylphosphatidylcholine

model membrane, fluidity, 22, 721

thermotropic properties, effects of ethanol, 22, 133

transitions, 22, 133

Diphenylhydantoin, effect on batrachotoxin binding, 22, 627

Diprenorphine, 3H-labeled, binding in intact cells, 22, 1

Distance geometry, benzodiazepine binding site, 22, 11

Diterpene, forskolin, effect on platelets (human), 21, 680

DNA

adduct, hepatic (rat), 22, 451

binding

correlation with anthracycline antitumor potency, 21, 196

correlation with nucleic acid synthesis inhibition, 21, 196

complementary, cloned, for P,-450 (mouse), 22, 779

cross-linking, in hypoxic leukemia cells (mouse), 22, 175

damage

fluorescence assay, 22, 145

phenacetin metabolite-induced, 22, 479

-dependent RNA polymerase, inhibition by rifamycins, 21, 394

-derived bases, molecular associations with Adriamycin, 22, 158

drug binding, acridine derivatives, 22, 486

5-fluorouracil incorporation, 21, 211

fragmentation and repair, 21, 211

inhibition, methotrexate (human), 21, 718

nucleotide levels, 21, 211

polymerase, inhibition (human), 21, 474

strand separation (mouse), 21, 739

synthesis, in cultured colon carcinoma cells (human), 21, 468

uracil incorporation, 21, 211

Dopamine

agonists (rat), 22, 281

comparison, 21, 114

3H-labeled

binding to caudate nucleus (calf), 22, 281

receptor binding (bovine), 21, 44, 52

receptor

SUBJECT INDEX 817

affinity states (porcine), 22, 298

anterior pituitary gland (porcine), 22, 290, 298

auto, y-aminobutyric acid technique (rat), 21, 114

auto-, synaptosomal tyrosine hydroxylation (rat), 21, 114

D-1, characterization (rat), 22, 281

D-1, model (rat), 22, 281

D-2 (bovine), 21, 44, 52

D-3 (bovine), 21, 44, 52

subtypes (bovine), 21, 44, 52

two affinity states (porcine), 22, 290

-sensitive adenylate cyclase

effects of sulihydryl groups (dog), 22, 595

striatal (rat), 22, 281

-sensitive adenylate cyclase complex, role of sulfhydryl groups in

coupling (dog), 22, 595

synthesis, autoreceptor control (rat), 21, 114

Dose-response curves, modification, 22, 369

“Down-regulation,” platelet alpha2-adrenergic receptors (human), 21,

36

Doxorubicin, see Adriamycin

Drug(s)

anxiolytic, quantitative structure-activity relationships, 22, 11

binding area, characterization in human serum albumin, 21, 387

design, chemotherapy, 22, 231

enzyme regulatory site-directed, 22, 231

intercalating, cellular effects (mouse), 21, 739

metabolism

in neonatal epidermis (rat), 21, 239

sexual differences (rat), 21, 744

nonsteroidal anti-inflammatory, structure-activity relationships, 22,

525

opiate, inhibition of phencycidine binding (ray), 22, 72

quatemary ammonium, interactions in Torpedo electric organ, 22,

63

resistance, in carcinoma cell line (rat), 21, 729

dThd kinase, virus-coded, 21, 432

dTMP kinase, virus-coded, 21, 432

dUMP, intracellular, effect of 5-fluorodeoxyuridine, 21, 211

dUTP, intracellular, effect of 5-fluorodeoxyuridine, 21, 211

Dynorphin binding sites, 21,266

E

Edrophomum

inhibition of acetylcholinesterase (ray), 22, 63

agonist and antagonist activity (ray), 22, 63

Effector blockade, modification of dose-response curves, 22, 369

Electron spin resonance, microsomal reduction of gentian violet (rat),

22, 239

Electrophoresis

coupled with immunochemical staining, 22, 787

cytochrome P-450, 22, 787

pulmonary cytochrome P-450 (rabbit), 22, 221

Eleptogenic property

$-alkyl-substituted -y-butyrolactones (mouse, guinea pig), 22, 431

unsubstituted y-butyrolactones (mouse, guinea pig), 22, 431

Embryo, brain, muscarinic receptors (chick), 21, 280

Enantiomer

aceclidine, binding in brain (rat), 21, 594

methotrimeprazine, differential stereoselectivity, 21, 315

Endocrine regulation of cadmium-sensitive hepatic cytochrome P-450

(rat), 22, 795

Endoplasmic reticulum

rough, epoxide hydratase activity (rat), 21, 511

smooth, epoxide hydratase activity (rat), 21, 511

Endorphin, effects in opiate addiction (rat), 22, 389

fl-Endorphinamphiphiic a- or ir-helix, 22, 657

interaction with calmodulin (bovine), 21, 86

model peptides, 22, 657

structural characteristics, 22, 657

End-plate current

amplitude, 22, 565

blockade, 21, 351

decay, 22, 565

effect of N-alkyl analogues (ray), 22, 82

neuromuscular (frog), 22, 636

time constant (frog), 21, 637

Energy-conformation calculations, 22, 667

Enkephalin

(D-A1a2, D-Leu5)-, binding sites, 21, 266

dimeric, affinity and selectivity for delta opiate receptor, 21, 558

effects in opiate addiction (rat), 22, 389

[3H}leucine

binding, effect of morphine (rat), 21, 538

binding in vitro, 21, 548

receptor, and morphine receptor, allosteric coupling in vitro, 21, 548

Enthalpy

binding, brain homogenates (rat), 22, 335

-driven binding process (rat), 22, 20

Entropy

binding, brain homogenates (rat), 22, 335

-driven binding process (rat), 22, 20

Environmental pollutants, effect on heme metabolism (rat), 21, 150

Enzyme

aromatase, catalysis, 21, 173

cardiac microsomal (fish), 21, 517

induction

phenobarbital (rat), 21, 511

trans-stilbene oxide (rat), 21, 511

liver, stereoselective metabolism of polycycic aromatic hydrocarbon

substrates (rat), 22, 182

microsomal, comparison, 22, 787

modulation, in KB cells (human), 21, 478

regulatory site-directed drugs, 22, 231

secretion

in parotid gland (rat), 21, 121

regulation (rat), 21, 121

Epidermis, neonatal, drug metabolism (rat), 21, 239

Epinephrine

inhibition of platelet adenylate cyclase (human), 22, 574

3H-labeled, alpha2-adrenergic receptors, 21, 17

pressure activity, 22, 725

Epoxide hydratase, nuclear envelope induction (rat), 21, 511

Epoxide hydrolase

activity in neonatal skin (rat), 21, 239

catalytic activity (human), 22, 190

liver microsomal (human), 22, 190

Epoxide stability, polycyclic aromatic hydrocarbons, 22, 459

Equilibrium

dialysis, cephalosporin-human serum albumin complexes, 21, 92

fluorescence, warfarin binding, 21, 100

Erythrocytes

cation fluxes (turkey), 21, 503

cyclic AMP receptors (turkey), 21, 503

free cholesterol transfer (human), 21, 694

insulin receptors, regulation by insulin and concanavalin A (frog), 22,

619

membrane, radioligand binding (frog, turkey), 21, 5

Erythroleukemia cell, cytoplasmic RNA, effect of anthracyclines, 22,

152

Erythrosine, effect on ouabain binding to digitalis receptor (rat, guinea

pig), 22, 687

Estrogen

biosynthesis, inhibition, 21, 173

receptor, translocation by SKF 525-A (rat). 21, 533

Estrogenic action, SKF 525-A (rat), 21, 533

818 SUBJECT INDEX

Ethanol, see also Alcohol

effect on dipalmitoylphosphatidylcholine, 22, 133

effect on free cholesterol transfer in erythrocytes (human), 21, 694

in vitro effects (rat, mouse), 22, 99

lipid effects, 22, 133

lipid solubiity, 22, 133

metabolism in perfused liver (rat), 21, 438

7-Ethoxycoumarin deethylase

Aroclor induction (rat), 21, 239

cytochrome P-450 inhibition, 21, 248

Ethoxyresorufin O-deethylase, activity in cardiac microsomes (fish),

21, 517

Ethylketocyclazocine binding sites, 21, 266

N-Ethylmaleimide

adenylate cyclase inhibition (dog), 22, 595

effect on pituitary dopamine receptors (porcine), 22, 298

receptor coupling (rat), 21, 570

5-Ethynyl-2’-deoxycytidine, antiherpes activity, 21, 217

Etorphine

binding to opiate receptors of caudate nucleus (sheep), 22, 648

“H-labeled

binding, 21, 548

receptor binding in vivo (rat), 21, 272

F

Fatty acids

effects on adenylate cyclase, 22, 360

effects on receptors, 22, 360

hydroperoxides, soluble guanylate cyclase activation (guinea pig), 21,

654

Flavin-containing monooxygenase, estimation, 22, 787

Flow cytometry

deoxyuridine treatment in lymphoblasts (human), 22, 166

methotrexate-treated cells, 21, 204

Fluidity, model membrane, 22, 721

Flunitrazepam

“H-labeled, kinetics of binding (rat), 21, 57

nonlinear van’t Hoff plot (rat), 22, 20

Fluorescence

enhancement assay for cellular DNA damage, 22, 145

equilibrium, warfarin binding, 21, 100

glucagon, 22, 105

quenching, DNA drug binding, 22, 486

stopped-flow, 21, 100

terbium, 22, 105

Fluoride, effect on hepatic and renal glucose-6-phosphatase activity

(rat), 22, 116

Fluorimetry

binding study, 21, 100

binding of warfarin to human serum albumin, 21, 100

5-Fluorodeoxyuridine

cytotoxicity, 21, 211

in gastrointestinal tumor (human), 21, 723

5-Fluoro-2’-deoxyuridine 5’-diphosphate, intracellular, effect of 5-fluo-

rodeoxyuridine, 21, 211

5-Fluoro-2’-deoxyuridine 5’-triphosphate, intracellular, effect of 5-fluo-

rodeoxyuridine, 21, 211

Fluorodeoxyuridylate, formation, 21, 224

5-Fluoro-5’-O-nitro-2’-deoxyuridine, cytotoxicity in L1210 cultures, 22,

760

5-Fluorouracil

DNA incorporation, 21, 211

effect on colon carcinoma cells in culture (human), 21, 468

interaction with N-(phosphonacetyl)-L-aspartate, 21, 224

-methotrexate combination, action in colon adenocarcinoma (hu-

man), 22, 771

5-Fluorouridine, effect on colon carcinoma cells in culture (human), 21,

468

Fluoxetine

inhibition of norepinephrine uptake, 21, 368

inhibition of serotonin uptake, 21, 362, 368

Fluxes

potassium, in erythrocytes (turkey), 21, 503

sodium, in erythrocytes (turkey), 21, 503

Folic acid analogue, release from hepatocytes (rat), 22, 493

Folinic acid, rescue effects in methotrexate-treated cells (human), 21,

718

Formaldehyde, cross-linking, methylmercury complexes in thymus

(calf), 22, 121

Forskolin

activation of adenylate cyclase in lymphoma cells, 22, 609

activation of cyclic AMP (rat), 22, 109

activation of lipolysis (rat), 22, 109

effect on adenylate cyclase (rat), 22, 109

effect on platelets (human), 21, 680

Fourier transform, ‘H, NMR studies on cytochrome P-450 (rabbit), 21,

701

Free-Wilsoman group contributions, theorem, 22, 725

Furan derivative, lung toxicity (rabbit), 22, 738

G

Gastric mucosa cells, interaction with histamine (guinea pig), 22, 33, 41

Gastrointestinal tumor

cytotoxicity of 5-fluorodeoxyuridine and methotrexate (human), 21,

723

thymidylate synthetase levels in cells (human), 21, 723

Genetic complementation, somatic mutants (mouse), 22, 204

Genetic mutation, single-gene (mouse), 22, 204

Genetics, adenylate cyclase (mouse), 22, 267, 274

Gentian violet, microsomal reduction (rat), 22, 239

Glioma cell, C6

calmodulin inhibitors, 22, 395

glycogen phosphorylase conversion, B to A, 22, 395

Glucagon

cation binding, 22, 105

circular dichroism, 22, 105

conformational change, 22, 105


fluorescence, 22, 105

zinc binding, 22, 105

Glucocorticoids, tyrosine hydroxylase induction (mouse), 22, 421

Glucose

oxidation, oxytocin stimulation (rat), 22, 381

transport

adipocyte, effects of adenosine (rat), 22, 614

effects of oxytocin (rat), 22, 381

Glucose-6-phosphatase

activity in kidney (rat), 22, 116

activity in liver (rat), 22, 116

elevation by fluoride (rat), 22, 116

Glucuronidation

benzo[a�pyrene metabolism (rat), 22, 451

rates, 7-hydroxycoumarin (rat), 22, 509

Glutamate-stimulated calcium uptake (rat, mouse), 22, 99

y-Glutamylcysteinylglycine, analogues (hydra), 21, 629

Glutathione

alkyl halide metabolism (rat), 22, 745

receptor, peptide interaction (hydra), 21, 629

Glycine, rescue effects in methotrexate-treated cells (human), 21, 718

Glycogen phosphorylase, conversion B to A in C6 glioma cells, 22, 395

Growth inhibition, cellular (human), 21, 718

GTPbinding, regulatory protein (bovine), 21, 52

regulation, dopamine receptors (bovine), 21, 52

GTPase

hormonal stimulation, 21, 336

SUBJECT INDEX 819

low Km, stimulation by inhibitors, 21, 336

Guanine nucleotide(s)

-activated cardiac adenylate cyclase activity (rat), 22, 342


effect

on binding in purified platelet membranes (human), 21, 600

on cardiac binding sites (rat), 21, 581

on pituitary dopamine receptors (porcine), 22, 290, 298

on prostaglandin E2 receptors in adipocytes (hamster), 22, 320

interaction with cardiac receptors (rat), 21, 570

receptor

regulation (guinea pig, bovine), 21, 329


-sensitive adenylate cyclase, effects of sulihydryl groups (dog), 22,

595

Guanosine-5’-triphosphate, effect on dopamine receptors (b*ine), 21,

52

Guanyl nucleotides, renal cortex (rat), 22, 589

Guanylate cyclase, myometrial (guinea pig), 21, 654

H

Haloethylnitrosoureas, selective cytotoxicity in carcinoma (rat), 21, 729

Halogen atoms, oxidation (rat), 22, 745

Halothane

effect on Ca2�-ATPase in cardiac sarcoplasmic reticulum (bovine),

22, 8

reductive metabolism by cytochrome P-450 (human, rabbit), 21, 710

Heart

digitalis receptor, inhibition of ouabain binding (guinea pig), 22, 687

hypertrophy, effect on muscarinic receptors (rat), 21, 589

membrane

adenylate cyclase activity (rat), 22, 342

muscarinic receptors (rat), 21, 581

microsomes

cytochrome P-450 activity (fish), 21, 517

monooxygenase activity (fish), 21, 517

mitochondrial ATPase, fluphenazine inhibition (bovine), 21, 415

muscarinic cholinergic receptor, interaction with guanine nucleotide

binding component (rat), 21, 570

muscarinic receptors (rat), 21, 581, 589

sarcoplasmic reticulum, effect of halothane (bovine), 22, 8

toxicity of anthracycline antineoplastic agents, 22, 471

Heat

inactivation, receptors in brain (rat), 22, 327

sensitivity, pituitary dopamine receptors (porcine), 22, 298

treatment, effect on dopamine receptors (bovine), 21, 52

HeLa cell, 9-fl-n-arabinofuranosyl-2-fluoroadenine inhibition (human),

21, 474

Heme

destruction by benzyl hydrodisulfide (rat), 21, 464

metabolism, effect of organometals (rat), 21, 150

oxygenase, effect of organometals (rat), 21, 150

Hemoglobin, tetrameric, subunit selectivity (rabbit), 21, 1

Hepatocyte

isolated, S-adenosylhomocysteine binding (rat), 21, 108

methotrexate release (rat), 22, 493

Hepatoxocity, norcocaine nitroxide (rat, hamster), 21, 458

Herpes simplex virus

inhibition by (E)-5-(2-bromovinyl)-2’-deoxyuridine, 21, 432

selective inhibitors, 21, 217

Heterogeneity

adenosine A, receptor binding in brain (rat, rabbit, guinea pig, calf,

human), 22, 250

binding (cat), 22, 304

species, adenosine receptor binding in brain (rat, rabbit, guinea pig,

calf, human), 22, 250

Histamine

agonist, effect on binding and biological response of gastric mucosal

cells (guinea pig), 22, 33

H, agonists, in polymorphonuclear neutrophils (human), 21, 78

H2 agonists, in polymorphonuclear neutrophils (human), 21, 78

H , antagonist


long-acting (rat, guinea pig), 21, 294

H2 antagonist

effect on binding and biological reponse of gastric mucosa cells

(guinea pig), 22, 41


interaction with gastric mucosal cells (guinea pig), 22, 33, 41

-mediated adenylate cyclase stimulation in myocardium (human),

21, 671

receptors

characterization in van deferens (mouse), 22, 602



surface, in promyelocytic leukemia cells (human), 22, 547

Histone, thymus

effect of methylmercury(II) (calf), 22, 121

formaldehyde cross-linking (calf), 22, 121

methylmercury complexes (calf), 22, 121

Histrionicotoxin

actions at ion channels, 21, 343

binding to electrically excitable membranes (ray), 22, 82

effect on neuromuscular transmission, 22, 565

H202, generation by hepatic cytochrome P-450 (rat), 22, 465

Hormone

inhibition, adenylate cyclase, 21, 336

stimulation, GTPase, 21, 336

Horseradish peroxidase-hydrogen peroxide oxidation of sulfite, 22, 732

Hybridization, blot

DNA (mouse), 22, 779


Hybridoma, monoclonal antibodies, 21, 248

Hydra feeding receptor, 21, 629

Hydration activity, carbon dioxide, of skeletal muscle (cat), 22, 211

Hydrocarbon, polycyclic aromatic

epoxide stability, 22, 459

stereoselective metabolism (rat), 22, 182

Hydrogen peroxide

hepatic microsomal metabolism (rabbit), 22, 471

-horseradish peroxidase oxidation of sulfite, 22, 732

Hydrolase, epoxide, activity in neonatal skin (rat), 21, 239

Hydroperoxide, fatty acid, soluble guanylate cyclase activation (guinea

pig), 21, 654

Hydrophobic interaction, Ca2�-calmodulin complex with calmodulin

antagonists, 22, 403

N-Hydroxyamphetamine

effect on hepatic cytochrome P-450 (rat), 22, 465

H202 generation (rat), 22, 465

4-Hydroxy-4-androstene-3,17-dione, inhibition ofestrogen biosynthesis,

21, 173

y-Hydroxybutyrate, eleptogenic properties (mouse, guinea pig), 22, 431

7-Hydroxycoumarin, sulfation and glucuronidation rates (rat), 22, 509

6-Hydroxydopamine, cytotoxic effect, 21, 363, 368

Hydroxyl group, rOle in phenylethanolamine N-methyltransferase sub-

strate activity, 22, 127

Hydroxyl radical, production, 21, 262

Hydroxylase, tyrosine, induction by glucocorticoids (mouse), 22, 421

N-Hydroxylase

induction in liver (rat), 21, 449

modification in liver (rat), 21, 449

Hydroxylation, benzo[a]pyrene, 21, 248

N-Hydroxynorcocaine, in vitro lipid peroxidation, 22, 529

N-Hydroxyphentermine

effect on hepatic cytochrome P-450 (rat), 22, 465

820 SUBJECT INDEX

dihydrofolate reductase (human), 21, 231

N-hydroxyphentermine-continued

H2O2 generation (rat), 22, 465

phentermine N-oxidation to (rabbit), 22, 235

8-Hydroxyquinoline, antimalarial activity, 22, 140

Hyperthyroidism, effect on cardiac muscarmnic receptors (rat), 21, 589

Hypertrophy, cardiac, effect on muscarmnic receptors (rat), 21, 589

Hypnotics, interaction with benzodiazepine receptors, 21, 320

Hypoglycemia, sulfonylureas, Ca2� ionophoretic activity (mouse), 22,

715

Hypothalamus

catecholamine uptake system (rat), 21, 374

synaptosomal protein carboxymethyltransferase (rat), 21, 181

Hypothermia, effect on muscannic agonist binding (rat), 21, 594

Hypothyroidism

effect on adipocytes (rat), 22, 109

effect on cardiac muscarinic receptors (rat), 21, 589

Hypoxia, leukemia cells, synergistic toxicity of misonidazole and sulfi-

docyclophosphamide (mouse), 22, 175

Ileum

I

binding of f�-endorphin, models (guinea pig), 22, 657

field-stimulated (guinea pig), 21, 259

Imidazolidines, X-ray structure, 21, 400

Immunochemical quantitation, flavin-containing monooxygenase, 22,

787

Immunochemical staining, coupled with electrophoresis, 22, 787

Immunochemistry

cytochrome P-450 (rat), 21, 744, 753

liver microsomal epoxide hydrolase (human), 22, 190

Immunodiffusion, radial, measurement of cytochrome P-450 concentra-

tion (rat), 21, 753

Immunoprecipitation, monoamine oxidase B, 22, 500

Immunoreactivity, antinucleoside (mouse), 21, 739

Imprinting, neonatal, and hepatic cytochrome P-450 (rat), 21, 744

Inactivation

heat, receptors in brain (rat), 22, 327

suicide

cytochrome P-450 (rat), 21, 166

hepatic arylhydroxamic acid N,O-acyltransferase (hamster), 21,

159

Inelastic electron tunneling spectroscopy, interaction of acetylcholine

and fl-methyl acetylcholine with alumina surface, 22, 678

Inflammation, role of neutrophils (rat), 21, 688

Inhibition

acetylcholinesterase (ray), 22, 63

S-adenosyl-L-methionine biosynthesis (rat), 22, 752

adenylate cyclase

by �:i+ (mouse), 22, 274

by Sc”� (mouse), 22, 274

in neuroblastoma cells, 21, 483

in renal cortex (rat), 22, 589

opiate, 21, 483

receptor-mediated (rat), 21, 570

[“H]batrachotoxinin A 20-a-benzoate binding, 22, 627

DNA, methotrexate (human), 21, 718

estrogen biosynthesis, 21, 173

human lymphoid, by antifolate BW3O1U, 22, 766

insulin secretion, alpha2-adrenergic receptor (rat), 21, 648

leukemia L1210 cells, by acndine derivatives (mouse), 22, 486

light-enhanced, ouabain binding to digitalis receptor (rat, guinea pig),

22, 687

liver cytochrome P-450 (rat), 21, 464

magnesium-dependent, heart soluble mitochondrial ATPase (bo-

vine), 21, 415

magnesium transport (mouse), 22, 274

metabolism, inhibition by antifolate BW3O1U (mouse), 22, 766

[3H]phencyclidine interactions with acetylcholine receptor channel

(ray), 22, 72

phenyl-N-methyltransferase, 22, 725

Plasmodium falciparum growth, by selected aromatic chelators, 22,

140

platelet adenylate cyclase (human), 21, 609; 22, 574

platelet cyclic AMP generation (human), 21, 680

prostaglandin synthesis (toad), 21, 142

protein kinase, 22, 408

protein synthesis in brain and liver (rat), 22, 706

quinone, hepatic (rat), 22, 451

RNA polyadenylation, 22, 517

skeletal muscle carbonic anhydrase (cat), 22, 211

synaptosomal protein carboxymethyltransferase (calf, rat), 21, 181

Inhibitor

adipocyte adenylate cyclase, 21, 336

calmodulin, in C6 glioma cells, 22, 395

microtubular, effect on Ca2�-transport ATPase, 22, 413


tricyclic, dopamine, in striatum and hypothalamus (rat), 21, 374

Insulin

binding sites, in erythrocytes (frog), 22, 619

-like activity of oxytocin (rat), 22, 381

receptors


down-regulation (frog), 22, 619

erythrocyte, regulation by insulin and concanavalin A (frog), 22,

619

regulation of insulin receptors in erythrocytes (frog), 22, 619

resistance, oxytocin and (rat), 22, 381

secretion, inhibition by alpha2-adrenergic receptors (rat), 21, 648

sensitivity, modulation by adenosine (rat), 22, 614

Intercalating drugs, cellular effects (mouse), 21, 739

5-Iodo-2’-deoxycytidine, antiherpes activity, 21, 217

(E)-5-(2-Iodovinyl)-2’-deoxycytidine, antiviral and antimetabolic prop-

erties, 21, 217

Ion

aziridinium, inhibition of norepinephrine uptake, 21, 380

channel

acetylcholine receptor, meproadifen reaction with (frog), 22, 636

activation, 22, 565

blockade, 21, 351; 22, 565

muscle membranes, 21, 351

neuroblastoma variants, 22, 196

nicotinic acetylcholine receptor, 21, 351

nicotinic acetylcholine receptor (ray), 22, 82

receptor (frog), 21, 637

nickel, modulation (rat), 22, 335

benzodiazepine receptor (mouse), 21, 618

role in adenylate cyclase inhibition (rat), 22, 589

transport, effect of anticonvulsant drugs, 22, 627

Ionophore

-a-aminobutyric acid complex, 21, 320

Ca2F


hypoglycemic sulfonylureas (mouse), 22, 715

Isomer, optical, methotrimeprazine, 21, 315

Isoproterenol, effect on cardiac adenylate cyclase activity (rat), 22,342

Isosafrole

induction of cytochrome P-450 subpopulations (rat), 21, 527

induction of cytochrome P,-450 (mouse), 22, 779

Isozyme

cytochrome P-450, catalytic activity (rabbit), 22, 738

mammalian ATP:L-methionine S-adenosyltransferase, differences in

active-site region (rat), 22, 752

purified microsomal, interaction with acet.anilide (rabbit), 21, 701

K

K� depolarization (mouse), 22, 715

KB cell

SUBJECT INDEX 821

effect on adenylate cyclase (mouse), 22, 267

methotrexate-resistant (human), 21, 231, 478

Ketanserin

functional role (rat), 21, 301

3H-labeledbinding properties (rat), 21, 301

selectivity (rat), 21, 301

Kidney

adenylate cyclase-coupled alpha2-adrenergic receptors (rat), 22, 589

effect of adrenalectomy (rat), 22, 116

glucose-6-phosphatase activity (rat), 22, 116

microsomes, cysteine S-conjugate N-acetyltransferase (rat), 21, 444

phenacetin toxicity, 22, 479

Kinase

protein

activation in parotid gland (rat), 21, 121

cyclic AMP, 21, 121

inhibition, 22, 408

thymidylate, virus-coded, 21, 432

Kinetics

N,O-acyltransferase inactivation (hamster), 21, 159

aryihydroxamic acid, suicide inactivation (hamster), 21, 159

binding

association and dissociation (rat), 21, 57

warfarin to human serum albumin, 21, 100

benzo[a]pyrene metabolism (rat), 22, 451

[3H]flunitrazepam binding (rat), 21, 57

opiate receptor binding (sheep), 22, 648

Km, low, GTPase, 21, 336

Lj�3+ inhibition of adenylate cyclase (mouse), 22, 274

Labeling, selective, serotonin-2 receptors (rat), 21, 301

Lecithin, egg vesicles, 21, 694

Lergotrile, effect on dopamine synthesis (rat), 21, 114

Leucine enkephalin, ‘H-labeled

binding in vitro, 21, 548

effect of morphine on binding (rat), 21, 538

Leukemia

cell, hypoxic, synergistic toxicity of misonidazole and sulfidocyclo-

phosphamide (mouse), 22, 175

L1210 cells

cytotoxicity of 5-fluoro-5’-O-nitro-2’-deoxyuridine, 22, 760

inhibition by acridine derivatives (mouse), 22, 486

promyelocytic cell line HL-60 (human), 22, 547

Levitimide, inhibition of binding in heart (rat), 21, 581

Levomepromazine, ring sulfoxidation, 21, 409

Ligand

adrenergic

liposolubiity in membranes (rat), 22, 5

n-octanol:water (rat), 22, 5

delta- and mu-, chronic treatment, cross-tolerance, 22, 1

3H-labeled, binding in caudate membrane (bovine), 21, 52

selective, for serotonin2 (rat), 21, 301

Lipid

acidic, cerebroside sulfate, 21, 492

effects of ethanol, 22, 133

effect on adenylate cyclase activity, 21, 492

effect on opiate inhibition, 21, 492

effect on opiates, 21, 492

incorporation in neuroblastoma N18TG2 cells, 21, 492

in vitro peroxidation, 22, 529

synthesis, adipocyte, effects of adenosine (rat), 22, 614

thermotropic properties, 22, 133

transition cooperativity, 22, 133

vesicles, free cholesterol transfer (human), 21, 694

Lipogenesis, oxytocin stimulation (rat), 22, 381

Lipolysis, forskolin activation in adipocytes (rat), 22, 109

Lipophiic chelator, antimalarial activity, 22, 140

Lipophiic-hydrophiic balance, antileukemic activity of acridine deny-

atives, 22, 486

Lipoproteins

free cholesterol transfer (human), 21, 694

high-density, free cholesterol transfer (human), 21, 694

low-density, free cholesterol transfer (human), 21, 694

Liposolubiity, adrenergic ligand in membranes (rat), 22, 5

Lipoxygenase

metabolism of arachidonic acid by neutrophils (rat), 21, 688

pathway, guanylate cyclase activation (guinea pig), 21, 654

Liver

N-acetyltransferase multiplicity (hamster), 21, 159

ATP concentration, effect of morphine (rat), 22, 706

cytochrome P-450

cadmium-sensitive (rat), 22, 795

inactivation (rat), 21, 166

induction with pregnenolone-16a-carbonitrile (rat), 21, 753

inhibition by benzyl hydrodisulflde (rat), 21, 464

neonatal imprinting and (rat), 21, 744

turnover (rat), 21, 744

subpopulations, induction by phenobarbital, /3-naphthoflavone,

and isosafrole (rat), 21, 527

cytochrome P,-450, mRNA (mouse), 22, 779

effect of adrenalectomy (rat), 22, 116

enzymes, stereoselective metabolism of polycyclic aromatic hydro-

carbon substrates (rat), 22, 182

glucose-6-phosphatase activity (rat), 22, 116

glucuronidation rates, 7-hydroxycoumarin (rat), 22, 509

microsomes

arylamide N-hydroxylase (rat), 21, 449

benzo[a]pyrene metabolism (rat), 22, 451

drug metabolism (rabbit), 22, 471

epoxide hydrolase (human), 22, 190

‘H Fourier transform NMR studies (rabbit), 21, 701


inhibition of oxidative drug metabolism (rabbit), 22, 471

metabolism of propyl halides (rat), 22, 745

mixed-function oxidase (rat), 21, 150

N-oxidation of phentermine (rabbit), 22, 235

perfused, ethanol metabolism (rat), 21, 438

plasma membrane, S-adenosylhomocysteine binding (rat), 21, 108

protein synthesis inhibition by morphine (rat), 22, 706

reconstituted cytochrome P-450 (rabbit), 22, 235

sulfation rates, 7-hydroxycoumarin (rat), 22, 509

toxicity, norcocaine nitroxide (rat, hamster), 21, 458

Lung

cytochrome P-450

isozymes, catalytic activity (rabbit), 22, 738

3-methylcholanthrene induction (rabbit), 22, 221

toxicity of 4-ipomeanol (rabbit), 22, 738

Lymphoblast, cultured, deoxyuridine metabolism (human), 22, 166

Lymphoid, inhibition by antifolate BW3O1U (human), 22, 766

Lymphoma cell

549, adenylate cyclase phenotypes (mouse), 22, 204

variant, adenylate cyclase activation, 22, 609

wild-type, adenylate cyclase activation, 22, 609

Lysosomatic amines, erythrocyte (frog), 22, 619

M

Magnesium


-dependent inhibition, heart soluble mitochondrial ATPase (bovine),

21, 415

regulation

of adenylate cyclase (mouse), 22, 267, 274

of beta-adrenergic receptor (mouse), 22, 267, 274

transport, inhibition (mouse), 22, 274

Malaria, human, treatment with lipophiic chelators, 22, 140

Manganese

822 SUBJECT INDEX

analogues, 21, 231

Manganese-continued

effect on opiate binding (rat), 21, 564

effect on receptor binding (mouse), 22, 267

Marcellomycin, effect on cytoplasmic RNA in erythroleukemia cells,

22, 152

Mass spectrometry, �2Cf plasma desorption (rat), 21, 688

Membrane

adipocyte, adrenergic ligand liposolubiity in (rat), 22, 5

-bound benzodiazepine receptors, kinetics of binding (rat), 21, 57

brain, opiate binding (rat), 21, 564

cardiac

adenylate cyclase activity (rat), 22, 342

muscarinic receptors (rat), 21, 581

caudate, “H-ligand binding sites (bovine), 21, 44, 52

electrically excitable, interaction with N-alkyl analogues (ray), 22,82

erythrocyte, free cholesterol transfer (human), 21, 694

islet cell, adenylate cyclase (rat), 21, 648

lipid

effects on adenylate cyclase, 22, 360

effects on receptors, 22, 360

liver plasma, S-adenosylhomocysteine binding (rat), 21, 108

model, fluidity, 22, 721

muscle, voltage-sensitive ion channels, 21, 351

nerve, sodium channel binding sites, 21, 343

plasma, Ca2ttransport ATPase (human), 22, 413

platelet, purified, binding (human), 21, 600

synaptosomal

binding sites (rat), 21, 57

cholinergic muscarinic receptor (cat), 22, 304

Meproadifen, effect on acetylcholine receptor (frog), 22, 636

Mesencephalic cell, primary culture, substance P derivative binding

(mouse), 22, 48

Metabolic activation

antineoplastic agents (rabbit), 22, 471

phenacetin metabolites, 22, 479

Metabolic-intermediate complexes, cytochrome P-450 (rat), 21, 527

Metabolism

N-alkyl compounds, 21, 133

anthracycline antineoplastic agents (rabbit), 22, 471

benzo[a]pyrene (fish), 21, 517

benzo[a�pyrene, kinetic determinants (rat), 22, 451

deoxyuridine, in lymphoblasts (human), 22, 166

drugs

in neonatal epidermis (rat), 21, 239

sexual differences (rat), 21, 744

ethanol, in perfused liver (rat), 21, 438

heme, effect of organometals (rat), 21, 150

inhibition, by antifolate BW3O1U (mouse), 22, 766

methotrexate, cellular (human), 21, 718

peroxidase, 21, 133

reductive, halothane, by cytochrome P-450 (human, rabbit), 21, 710

stereoselective, chrysene 1,2-dihydriols (rat), 22, 182

Metabolite

active, chioramphenicol (rat), 21, 166

arachidonic acid, stimulation of neuroblastoma adenylate cyclase, 21,

664

chlorpromazine, ring sulfoxidation, 21, 409

cocaine, hepatotoxicity (rat, hamster), 21, 458

methotrimeprazine, ring sulfoxidation, 21, 409

phenacetin, activation, 22, 479

sulfoxide, effect on neuroleptic potency, 21, 409

Methiodide, aceclidine, binding in brain (rat), 21, 594

Methionine adenosyltransferase, tumor and normal, substrate specific-

ities (rat), 22, 752

L-Methionine, analogues, substrate and inhibitory properties (rat), 22,

752

Methotrexate

catecholamine-induced release from hepatocytes (rat), 22, 493

cellular effects, 21, 204

cytotoxicity (human), 21, 718

in gastrointestinal tumor, 21, 723

effect on dihydrofolate reductase activity (human), 21, 478

5-fluorouracil combination, action in colon adenocarcinoma (human),

22, 771lymphoblastoid resistance (human), 22, 766

metabolic inhibition in mouse cell lines, 22, 766

metabolism, cellular (human), 21, 718

polyglutamates, accumulation in cells (human), 21, 718

-resistant KB cells (human), 21, 231, 478

-treated cells, rescue agents (human), 21, 718

Methotrimeprazine

enantiomers, differential stereoselectivity, 21, 315

optical isomers, 21, 315

ring sulfoxidation, 21, 409

fl-Methyl acetylcholine, interaction with alumina surface, 22, 678

3-Methylcholanthrene, induction

cytochrome P,-450 (mouse), 22, 779

liver microsomes, benzo[a]pyrene metabolism (rat), 22, 451

pulmonary cytochrome P-450 (rabbit), 22, 221

Methylmercury II, effect on histones (calf), 22, 121

Methyltransferase, phospholipid, in liver plasma membranes (rat), 21,

108

Microcalorimetry, cephalosporin-human serum albumin complexes, 21,

92

Microsome

cardiac, cytochrome P-450 and monooxygenase activity (fish), 21,

517

enzymes, comparison, 22, 787hepatic

arylamide N-hydroxylase (rat), 21, 449

benzo[a}pyrene metabolism (rat), 22, 451

drug metabolism (rabbit), 22, 471

epoxide hydrolase (human), 22, 190

‘H Fourier transform NMR studies (rabbit), 21, 701


inhibition of oxidative drug metabolism (rabbit), 22, 471

metabolism of propyl halides (rat), 22, 745

3-methylcholanthrene-induced (rat), 22, 451

reduction of gentian violet (rat), 22, 239

renal, cysteine S-conjugate N-acetyltransferase (rat), 21, 444

Misonidazole, cytotoxicity, synergism with sulfidocyclophosphamide

(mouse ), 22, 175

Mitochondria, heart ATPase, fluphenazine inhibition (bovine), 21, 415

Mitoxantrone, hepatic microsomal metabolism (rabbit), 22, 471

Model membrane, fluidity, 22, 721

Molecular conformation, solid-state, 21, 409

Molecular orbital calculations, polycycic aromatic hydrocarbon epox-

ide stability, 22, 459

Molecular shape analysis, 1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187

Molecular structure, 3-carbomethoxy rifamycin 5, 21, 394

Monoamine oxidase

Bimmunoprecipitation, 22, 500

monoclonal antibody to, 22, 500

pargyline labeling, 22, 500


separation of A and B, 22, 500

Monoclonal antibody

distinction of monoamine oxidase A and B, 22, 500

hybridoma, 21, 248

to cytochrome P-4SOLM2 and P-450LM4, 21, 248

to monoamine oxidase B (human), 22, 500

Monohydroxyaminotetralins

enantiomeric, effect on dopamine binding (rat), 22, 281

racemic, effect on dopamine binding (rat), 22, 281

SUBJECT INDEX 823

Monooxygenase

activity, in cardiac microsomes (fish), 21, 517

-like activity, of tetrameric hemoglobin (rabbit), 21, 1

reconstituted system (rat), 21, 166

Morphine

effect on ATP concentration in brain and liver (rat), 22, 706

effect on binding of [3H]leucine enkephalin (rat), 21, 538

effect on blood pH, Po2, and Pco2 (rat), 22, 706

effect on calmodulin activity in brain (rat), 22, 389

effect on protein synthesis in brain and liver (rat), 22, 706

receptors, and enkephalin receptors, allosteric coupling in vitro, 21,

548

Morphology, cellular transformation (mouse), 21, 739

Mucosa, fundic, cells, interaction with histamine (guinea pig), 22, 33,

41

Muscarinic receptor

binding, aceclidine and its methiodide (rat), 21, 594

central (cat), 22, 304

cholinergic

activation of phosphodiesterase, 22, 310

effect of phencyclidine (frog), 21, 637

synaptosomal membrane (cat), 22, 304

Muscle

cloned cell line, BC3H-1 (mouse), 22, 258

denervated (frog), 22, 636

membrane, voltage-sensitive ion channels, 21, 351

skeletal

action potential (frog, ray), 22, 82

carbonic anhydrase, carbon dioxide hydration activity (cat), 22,

211

twitcheffect of meproadifen (frog), 22, 636

effect of N-alkyl analogues of amantadine (frog), 22, 82

Mutagenic effect, sodium channels, 22, 196

Mutagenicity, Ames test, 21, 187

Mutant, somatic, genetic complementation (mouse), 22, 204

Mutation, single-gene (mouse), 22, 204

Myocardium, histamine-mediated adenylate cyclase stimulation (hu-

man), 21, 671

Myometrium

carbachol, phospholipase A2 activation (guinea pig), 21, 654

guanylate cyclase (guinea pig), 21, 654

N

NADH dehydrogenase, hepatic microsomal (rabbit), 22, 471

NADPH-cytochrome P-450 reductase, hepatic microsomal (rabbit), 22, 471

oxidation, hepatic microsomal (rabbit), 22, 471

Na,K-ATPase

ADP-sensitive, phosphoenzyme-rich (electric eel), 22, 693

conversion of ADP-sensitive to K�-sensitive phosphorylated forms

(electric eel), 22, 693

oligomycin interaction (electric eel), 22, 693

phosphorylated intermediate

ADP-sensitive (electric eel), 22, 693

interaction with ouabain (electric eel), 22, 700

Naloxone

3H-labeled, binding in brain (rat), 22, 349

prevention of acute effect of morphine on protein synthesis in brain

and liver (rat), 22, 706

Naphthalenesulfonamide derivatives

effect on Ca2�-calinodulin complex, 22, 403

phosphorylation modulation, 22,408

$-Naphthoflavone, induction of cytochrome P-450 subpopulations

(rat), 21, 527

Narcotic analgesia, 21, 548

Neonate, imprinting, and hepatic cytochrome P-450 (rat), 21, 744

Nephrotoxicity, phenacetin-induced, 22, 479

Nerve membrane, sodium channel binding sites, 21, 343

Neuroblastoma cells

cultured, adenylate cyclase, 21, 664

x glioma hybrid

adenylate cyclase activity, 22, 360


x glioma NG1O8-15 hybrid



opiate receptor activity, 22, 1

N18TG2


potentiation of opiate action, 21, 492


tyrosine hydroxylase induction (mouse), 22, 421

variant clones, characterization, 22, 196

Neuroleptic potency, effect of ring sulfoxidation, 21, 409

Neuroleptics, effect on glycogen phosphorylase, 22, 395

Neuromuscular blockade, pumiliotoxin-C, 22, 565

Neuromuscular junction, desensitization (frog), 22, 636

Neuromuscular transmission, effect of meproadifen (frog), 22, 636

Neuronal cell, culture (mouse), 22, 48

Neutrophil

formation of diarachidonyl diglyceride (rat), 21, 688

functions (human), 21, 78

peripheral (human), 22, 547

polymorphonuclear, histamine receptors (human), 21, 78

Nickel ion, modulation (rat), 22, 335

Nicotine, binding in brain (mouse), 22, 554

Nicotinic acid, prostaglandins, 21, 336

Nicotimc antagonists, binding, 22, 565

Nicotinic receptor


effect of phencyclidine (frog), 21, 637

5-Nitro-2’-deoxycytidine, antiherpes activity, 21, 217

Nitrogen

bifunctional mustards, carcinoma cell line resistance (rat), 21, 729

oxidation, cytochrome P-450-dependent (rabbit), 22, 235

Nitrosoureas, selective cytotoxicity in carcinoma (rat), 21, 729

Nonlinear least-squares curve fitting, insulin binding study (frog), 22,

619

Norcocaine nitroxide

induced hepatotoxicity (rat, hamster), 21, 458

in vitro lipid peroxidation, 22, 529

Norepinephrine

inhibition of serotonin uptake, 21, 362

uptake

in pheochromocytoma cells, 21, 368

inhibition by xylamine, 21, 380

Norfenfluramine, conformationally defined analogues, 22, 127

Nuclear envelope, epoxide hydratase, inducibility (rat), 21, 511

Nuclear magnetic resonance

cephalosporin-human serum albumin complexes, 21, 92

‘H3-carbomethoxy rifamycin 5, 21, 394

Fourier transform, cytochrome P-450 (rabbit), 21, 701

Nuclear structure, effect of nitrosoureas (rat), 21, 729

Nucleoside

adenine, effects on RNA synthesis, 22, 517

molecular associations with Adriamycin, 22, 158

Nucleotide(s)

guanine-activated cardiac adenylate cyclase activity (rat), 22, 342


effect on cardiac binding sites (rat), 21, 581

effect on pituitary dopamine receptors (porcine), 22, 290, 298

effect on prostaglandin E2 receptors in adipocytes (hamster), 22,

320

824 SUBJECT INDEX

Nucleotide-continued

guanine-continued

interaction with cardiac receptors (rat), 21, 570

receptor regulation (guinea pig, bovine), 21, 329

receptor regulation (rat), 22, 532

guanyl, renal cortex (rat), 22, 589

levels in cells treated with 5-fluorodeoxyuridine, 21, 211

molecular association with Adriamycin, 22, 158

pyrimidine, biosynthesis, 21, 224

Nucleus

histones, effect of methylmercury (II) (calf), 22, 121

thymus, formaldehyde cross-linking (calf), 22, 121

0

Oligomycin, inhibition of ADP-sensitive K�-sensitive change (electric

eel), 22, 693

Opiate

action, potentiation in neuroblastoma N18TG2 cells, 21, 492

addiction, effects on calmodulin activity (rat), 22, 389

agonist

binding model (rat), 22, 349

potency and efficacy, 21, 483

alkaloids, in brain (rat), 21, 564

analgesia (rat), 21, 272

antagonist, binding model (rat), 22, 349

chronic treatment, effect on opiate receptor activity, 22, 1

delta-, receptor site, 21, 266

drugs, inhibition of phencycidine binding (ray), 22, 72

effect, chronic, 21, 483

inhibition

adenylate cyclase activity, 21, 483

adenylate cyclase, Na� and GTP effect, 21, 483

interaction with phencyclidine (ray), 22, 72

kappa-, receptor site, 21, 266

mu-, receptor site, 21, 266

receptor

binding, 21, 483, 492

binding in brain (rat), 21, 564

binding models (rat), 21, 272


caudate nucleus, etorphine binding (sheep), 22, 648

delta, 21, 558

desensitization, 22, 1

down regulation, time course, 22, 1

effect relationship (rat), 21, 272

in neuroblastoma x glioma NG1O8-15 hybrid cells, 22, 1

in vivo binding (rat), 21, 272


multiple (rat), 21, 564

multiple, coupling in vitro, 21, 548

multiple, in brain (rat), 21, 538

multiple sites, 21, 266

various brain areas (rat), 22, 389

sigma receptor site, 21, 266

tetrapeptide, conformational-energy studies, 22, 667

Optical isomer, methotrimeprazine, 21, 315

Opioid

peptides


interaction with /3-endorphin (bovine), 21, 86

receptor

allosteric effects, 21, 548

allosteric effects (rat), 21, 538

binding, two-state model (rat), 22, 349

Organometals, effect on heme metabolism (rat), 21, 150

Ouabain

binding to digitalis receptor (rat, guinea pig), 22, 687

interaction with phosphorylated intermediate ofNa,K-ATPase (elec-

tric eel), 22, 700

Overlap, with fused ring opiates, 22, 667

Oxidase

cytochrome P-450, N-oxidation of phentermine (rabbit), 22, 235

mixed-functionbenzo[a]pyrene oxygenation, 21, 248

hepatic (rat), 21, 150

in neonatal skin (rat), 21, 239

monamine

B, immunoprecipitation, 22, 500

B, monoclonal antibody to, 22, 500

B, pargyline labeling, 22, 500


separation of A and B, 22, 500

Oxidation

horseradish peroxidase-hydrogen peroxide, of sulfite, 22, 732

NADPH, hepatic microsomal (rabbit), 22, 471

nitrogen, cytochrome P-450-dependent (rabbit), 22, 235

phentermine, cytochrome P-450-dependent (rabbit), 22, 235

N-Oxidation, phentermine, by cytochrome P-450 oxidase system (rab-

bit), 22, 235

Oxine derivatives, antimalarial activity, 22, 140

Oxotremorine


3H-labeled, binding in heart (rat), 21, 581, 589

Oxygenase, heme, effect of organometals (rat), 21, 150

Oxytocin

action in adipocytes (rat), 22, 381

adipocyte receptors (rat), 22, 381

analogues, action in adipocytes (rat), 22, 381

glucose transport (rat), 22, 381

insulin-like activity (rat), 22, 381

insulin resistance (rat), 22, 381

stimulation of glucose oxidation (rat), 22, 381

stimulation of lipogenesis (rat), 22, 381

stimulation of pyruvate dehydrogenase (rat), 22, 381

P

Pancreas islets

calcium transport (mouse), 22, 715

cyclic AMP generation (rat), 21, 648

Parinaric acid, absorbance in lipid, 22, 133

Pargyline, labeling of monoamine oxidase B, 22, 500

Parotid cell, alpha,-adrenergic stimulation (rat), 21, 128

Parotid gland

phosphatidylinositol-phosphatidic acid turnover (rat), 21, 128

protein kinase activation (rat), 21, 121

Partition coefficient, adrenergic ligand liposolubiity (rat), 22, 5

Peptide

interaction of glutathione receptor of hydra, 21, 629

opioid


interaction with calmodulin (bovine), 21, 86

Permeability, potassium (frog), 21, 637

Pergolide, effect on dopamine synthesis (rat), 21, 114

Peroxidase metabolism, 21, 133

Peroxidation, lipid, in vitro, 22, 529

Pharmacological shift ratio, definition, 22, 580

Pharmacophore, benzodiazepine, 22, 11

Phase transitions, dipalmitoylphosphatidylcholine, 22, 133

Phenacetin metabolites, activation, 22, 479

Phencycidine

analogues (frog), 21, 637


behavioral effects (frog), 21, 637

binding to channel sites (ray), 22, 72

3H-labeled

binding to channel sites (ray), 22, 63

interaction with nicrotinic acetylcholine receptor channel (ray),

SUBJECT INDEX 825

22, 72

potassium permeability (frog), 21,637

Phenobarbitalenzyme induction (rat), 21, 511

induction of cytochrome P-450 subpopulations (rat), 21, 527

induction of hepatic cytochrome P450 (rat), 21, 753

Phenotype, adenylate cyclase, in S49 lymphoma cells (mouse), 22, 204

Phenoxybenzamine, dopamine receptor alkylation (bovine), 21, 44

Phentermine

oxidation, cytochrome P-450-dependent (rabbit), 22, 235

N-oxidation, by cytochrome P-450 oxidase system (rabbit), 22, 235

1-(X-Phenyl)-3,3-dialkyltriazenes

Ames test, 21, 187

antitumor activity, 21, 187

Phenylethanolamine, trifluoromethyl-substituted, 22, 127

Phenylethanolamine N-methyltransferase

inhibition, 22, 127

substrates, 22, 127

Phenylethylamine

conformationally defined analogues, 22, 127

pharmacological activity, 22, 725

Phenylisopropyladenosine, effects on glucose transport (rat), 22, 614

Phenyl-N-methyltransferase

inhibition, 22, 725

substrate activity, 22, 725

N-Phenylnaphthylamine, in study of membrane fluidity, 22, 721

Phenyltriazenes, molecular shape analysis, 21, 187

Pheochromocytoma cellsnorepinephrine uptake, 21, 368


Phosphatidic acid, turnover in parotid cells (rat), 21, 128

Phosphatidylinositol, turnover in parotid cells (rat), 21, 128

Phosphodiesterase

Ca2�-dependent activation, 22, 310

muscarinic cholinergic receptor-mediated activation, 22, 310

Phospholipid

binding of 1-chloro-2,2,2-trifluoroethyl radical (human, rabbit), 21,

710

methyltransferase, in liver plasma membranes (rat), 21, 108

vesicles, egg lecithin (human), 21, 694

N-(Phosphonacetyl)-L-aspartate, interaction with 5-fluorouracil, 21,

224

5-Phosphoribosyl-1-pyrophosphate, effect of methotrexate-5-fluorour-

acil on concentrations in colon xenografts (human), 22, 771

Phosphorylase, glycogen, conversion B to A in C6 glioma cells, 22, 395

Phosphorylated intermediate

ADP-sensitive, in Na,K-ATPase preparation (electric eel), 22, 693

Na,K-ATPase, interaction with ouabain (electric eel), 22, 700

Phosphorylation

Ca24-calmodulin-dependent, 22, 408

protein, in human platelets, 21, 422

Photoaffinity labeling

erythrocytes (turkey), 21, 503

sparing of fI-carboline binding (mouse), 21, 618

Picrotoxin binding sites, in brain (rat), 22, 327

Picrotoxinin, structure-activity relationships (mouse, guinea pig), 22,

444

Piocarpine binding in heart (rat), 21, 581

Pituitary gland

anterior

dopamine receptor (porcine), 22, 290, 298

prolactin secretion (porcine), 22, 298

effects on hepatic cytochrome P-450 (rat), 22, 795

Plasma desorption, 252Cf, mass spectrometry (rat), 21, 688

Plasma membrane, Ca2�-transport ATPase (human), 22, 413

Plasmodium falciparum, inhibition by selected aromatic chelators, 22,

140

Plasticity, synaptic, 21, 280

Platelet(s)

adenylate cyclase (human), 22, 574

alpha2-adrenergic receptors (human), 21, 36, 609; 22, 574

calcium mobilization, effect of trifluoperazine (human), 21, 422

inhibition of aggregation (human), 21, 680

membranes, purified, binding (human), 21, 600

monoamine oxidase, monoclonal antibody to (human), 22, 500

protein phosphorylation, effect of trifluoperazine (human), 21, 422

secretion and aggregation, effect of trifluoperazine (human), 21, 422

storage of biogenic amines (human), 22, 94

Pollutants, environmental, effect on heme metabolism (rat), 21, 150

Polyadenylation, RNA, inhibition, 22, 517

Poly(A)�-RNA, synthesis, 22, 152

Polycyclic aromatic hydrocarbons

carcinogenic, epoxide stability, 22, 459

stereoselective metabolism (rat), 22, 182

Polyglutamates, methotrexate, accumulation in cells (human), 21, 718

PolymeraseDNA, inhibition (human), 21, 474

DNA-dependent RNA, inhibition by rifamycin, 21, 394

Polysome

brain, effect of morphine (rat), 22, 706

liver, effect of morphine (rat), 22, 706

Potassiumfluxes, in erythrocytes (turkey), 21, 503

permeability (frog), 21, 637

-stimulated calcium uptake (rat, mouse), 22, 99

Potentiation, opiate action, in neuroblastoma N18TG2 cells, 21, 492

Prazosin, 3H-labeled

alpha,-adrenergic receptor (mouse), 22, 258

binding in renal cortex (rat), 22, 532

Pregnenolone-16a-carbonitrile

effect on hepatic tyrosine aminotransferase (rat), 21, 753

induction of hepatic cytochrome P-450 (rat), 21, 753

Prolactin secretion

anterior pituitary gland (porcine), 22, 298

control (porcine), 22, 290

n-Propylapomorphine, 3H-labeled, binding in pituitary (porcine), 22,

290, 298

N-n-Propylapomorphine, effect on dopamine synthesis (rat), 21, 114

5-Propyl-2’-deoxycytidine, antiherpes activity, 21, 217

Propyl $-carboline-3-carboxylate, 3H-labeled, binding (mouse), 21, 618

Propyl halides, metabolism in liver (rat), 22, 745

N-n-Propyl-3-(hydroxyphenyl)-piperidine, effect on dopamine synthe-

sis (rat), 21, 114

3,3’-[(Propylimino)di-2,1-ethanediyl]bis[phenol], effect on dopamine

synthesis (rat), 21, 114

Prostacyclin, stimulation of cyclic AMP in cultured neuroblastoma, 21,

664

Prostaglandin

activation of platelet adenylate cyclase (human), 21, 680

biosynthesis, N-alkylation during, 21, 133

E, immunoreactiye (toad), 21, 142

E2

binding regulation (hamster), 22, 320

receptor in adipocytes (hamster), 22, 320

effect on cultured thyroid cells (porcine), 21, 66

inhibition of platelet aggregation (human), 21, 680

nictotinic acid, 21, 336

receptors



stimulation of cyclic AMP in cultured neuroblastoma, 21, 664

synthesis, inhibition (toad), 21, 142

synthetase

-catalyzed activation of phenacetin metabolites, 22, 479

co-oxidation, 21, 133

Protein

brain, synthesis inhibition by morphine (rat), 22, 706

carboxy O-methylation, 21, 181

826 SUBJECT INDEX

Protein-continued

coupling, adenylate cyclase, magnesium regulation (mouse), 22, 267

�nase

activation in parotid gland (rat), 21, 121

cyclic AMP (rat), 21, 121

inhibition, 22, 408

liver, synthesis inhibition by morphine (rat), 22, 706

molecular association with Adriamycin, 22, 158

phosphorylation, in human platelets, 21, 422

synaptosomal, carboxymethyltransferase (calf, rat), 21, 181

Proteolysis, $-endorphin model peptides, 22, 657

Proton gradient, role in biogenic amine storage in platelets (human),22, 94

Psychotropic drugs, inhibition of phencyclidine binding (ray), 22, 72

Pumiliotoxin-C, effect on neuromuscular transmission, 22, 565

Pyrimidine

antifolate derivative, metabolic inhibition (mouse), 22, 766

fluorinated derivative, cytoxicity in L1210 cultures, 22, 760

nucleotide, biosynthesis, 21, 224

Pyrromycin, effect on cytoplasmic RNA in erythroleukemia cells, 22,

152

Pyruvate dehydrogenase, oxytocin stimulation (rat), 22, 381

QQuantum chemical analysis, structure-activity relationships, 22, 525

Quantum mechanical analysis, clonidine, 21,400

Quaternary ammomum

agonists and antagonists (ray), 22, 63

drugs, interactions in Torpedo electric organ, 22, 63

Quinone inhibition, hepatic (rat), 22, 451

Quinuclidinyl benzilate


binding in heart (rat), 21, 589

‘H-labeled

binding in astrocytoma cells (human), 22, 310

binding in heart (rat), 21, 581

L-Quinuclidinyl benzilate, 3H-labeled, heterogeneity of binding sites in


R

Radical

free, carbon-centered (rat), 22, 239

hydroxyl, production, 21, 262

Radioligand binding, computer modeling, 21, 5

Receptor

acetylcholine

drug specificity (ray), 22, 63

in soleus muscle (rat), 22, 565



nicotinic, 21, 351

adenosine A,

binding heterogeneity (rat, rabbit, guinea pig, calf, human), 22,250

binding in brain (guinea pig, bovine), 21, 329

adenylate cyclase-coupled, anterior pituitary gland (porcine), 22, 298

adrenergic, see Adrenergic receptor

y-aminobutyric acid, modulation of cation binding sites (rat), 22, 327

auto-, in dopamine synthesis (rat), 21, 114

autonomic, in submandibular gland (rat), 21, 27

benzodiazepine

y-aminobutyric acid regulation (mouse), 21, 618

chloride channel regulation (mouse), 21, 618

heterogeneity (mouse), 21, 618


interaction with barbiturates, 21, 320

interconvertible conformations (rat), 21, 57

ion regulation (mouse), 21, 618

membrane-bound (rat), 21, 57

temperature dependence of interaction (rat), 22, 20

binding

$-endorphin models, 22, 657

guamne nucleotide regulation (hamster), 22, 320

monovalent cations (hamster), 22, 320

central nervous system, in vitro, 21, 315

cholinergic muscarinic (mouse), 22, 554


cholinergic nicotinic (mouse), 22, 554

complexes, in brain (rat), 22, 327

coupling

adenylate cyclase (bovine), 21, 52

adenylate cyclase, allozyme hypothesis, 22, 580

N-ethylmaleimide (rat), 21, 570

cross-linking, 21, 558

-cyclase coupling (mouse), 22, 204

cyclic AMP, in erythrocytes (turkey), 21, 503

digitalis, light-enhanced inhibition of binding (rat, guinea pig), 22,

687

dopamine

affinity states (porcine), 22, 298

anterior pituitary gland (porcine), 22, 290, 298

D-1, characterization (rat), 22, 281

D-2 (bovine), 21, 44, 52

D-3 (bovine), 21, 44, 52

subtypes (bovine), 21, 44, 52

two affinity states (porcine), 22, 290

-drug interactions, nonspecific, 22, 725

-effector coupling, in platelets (human), 21, 609

estrogen, translocation by SKF 525-A (rat), 21, 533

[3Hjetorphine, binding in vivo (rat), 21, 272

glutathione, peptide interaction (hydra), 21, 629

guanine nucleotide regulation (rat), 22, 532

histamine

characterization in vas deferens (mouse), 22, 602



sensitivity to H, and H2 agonists and antagonists (mouse), 22, 602

inhibition of platelet adenylate cyclase (human), 22, 574

insulin’


erythrocyte, regulation by insulin and concanavalin A (frog), 22,

619

interactions, thermodynamics (rat, rabbit, guinea pig, caff, human),

22, 250


kinetics, reserve, 22, 369

-mediated inhibition, adenylate cyclase (rat), 21, 570


muscarinic

antiestrogen interaction (rat), 21, 287

binding of acecidine and its methiodide (rat), 21, 594

cardiac (rat), 21, 581, 589

central (cat), 22, 304

muscarinic cholinergic

activation of phosphodiesterase, 22, 310

characterization (porcine), 21, 66

effect of phencycidine (frog), 21, 637

interaction with guanine nucleotide binding component (rat), 21,

570

in vivo regulation (chick), 21, 280

on cultured thyroid cells (porcine), 21, 66, 73

nicotinic

effect of N-alkyl analogues of amantadine (frog, ray), 22, 82

effect of phencycidine (frog), 21, 637

nicotinic acetylcholine

binding sites (ray), 22, 72

channel, interactions with {‘3H]phencyclidine (ray), 22, 72

SUBJECT INDEX 827

messenger

ion channel, 21, 351

ionic channels, interaction with N-alkyl analogues of amantadine

(ray), 22, 82

neuromuscular (frog), 22, 636

receptor/channel, binding (ray), 22, 63

nicotinic cholinergic, in brain (rat), 22, 56

occupancy/effect relationship, 22, 574

opiate

binding, 21, 483, 492

binding, effect relationship (rat), 21, 272


binding models (rat), 21, 272


caudate nucleus, etorphine binding (sheep), 22, 648

delta, 21, 558

desensitization, 22, 1

down regulation, time course, 22, 1

in neuroblastoma x glioma NG1O8-15 hybrid cells, 22, 1


multiple (rat), 21, 564

multiple, coupling in vitro, 21, 548


multiple sites, 21, 266

various brain areas (rat), 22, 389

opioidallosteric effects, 21, 548

allosteric effects (rat), 21, 538

two-state binding model (rat), 22, 349

oxytocin, adipocyte (rat), 22, 381

presynaptic, conformational requirements, 21, 259

prostaglandin

E2, adipocyte (hamster), 22, 320



regulation

cations (guinea pig, bovine), 21, 329

guanine nucleotide (guinea pig, bovine), 21, 329

saxitoxin, 21, 343

serotonin, characterization in brain (rat), 22, 243

site

delta-opiate, 21, 266

kappa-opiate, 21, 266

mu-opiate, 21, 266

sigma-opiate, 21, 266

sodium regulation (rat), 22, 532

substance P, in mesencephalic cells (mouse), 22,48

subtypes, computer modeling method for binding data, 21, 5

surface, for histamine (human), 22, 547

Torpedo electric organ, 22, 63, 72

turnover in cultured thyroid cells (porcine), 21, 73

Rectification, delayed (frog), 21, 637

Reductase

cytochrome P-450, hepatic microsomal (rabbit), 22, 471

ribonucleotide, inhibition (human), 21, 474

Reduction, microsomal, gentian violet (rat), 22, 239

Regulation, enzyme secretion in parotid gland (rat), 21, 121

Regulatory site, antagonist, 22, 231

Relaxation rates, T,, substrate-cytochrome P-450 complexes (rabbit),

21, 701

Renal cortex

adenylate cyclase-coupled alpha2-adrenergic receptors (rat), 22, 589

alpha-adrenergic receptors (rat), 22, 532

Ribonucleotide reductase, inhibition (human), 21, 474

Rifamycin, C(3) derivatives, 21, 394

Ho 5-4864, 3H-labeled, characterization of benzodiazepine binding sites

(rat), 22, 26

RNA

cytochrome P,-450 (mouse), 22, 779

effect of anthracyclines, 22, 152

nuclear

colon carcinoma cells in culture (human), 21, 468

transport, 22, 152

polyadenylation, inhibition, 22, 517

polymerase, DNA-dependent, inhibition by rifamycin, 21, 394

synthesis

adenovirus, 22, 517

effects of ademne nucleosides, 22, 517

in cultured colon carcinoma cells (human), 21, 468

total, effect of anthracyclines, 22, 152

R0t analysis, hepatic cytochrome P,-450 (mouse), 22, 779

RU-24926, see 3,3’-[(Propylimino)di-2,1-ethanediyl]bis[phenol]

S

5180 AT/3000 cell, dihydrofolate reductase (mouse), 21, 231

Sarcoplasmic reticulum, cardiac

Ca2�-ATPase (bovine), 22, 8

effect of halothane (bovine), 22, 8

Saxitoxin

binding site, structure, 21, 343

nonspecific binding, 21, 343

receptor, 21, 343

Sc”4, inhibition of adenylate cyclase (mouse), 22, 274

Scatchard linearization, 21, 564

Secretin, effect on cardiac adenylate cyclase activity (rat), 22, 342

Secretion

enzyme

in parotid gland (rat), 21, 121


prolactin

anterior pituitary gland (porcine), 22, 298

control (porcine), 22, 290

stimulus-induced, in human platelets, 21, 422

Secretory granule, isolated, calcium transport (mouse), 22, 715

Sedatives, interaction with benzodiazepine receptors, 21, 320

Selectivity

colon xenografts (human), 22, 771

for delta opiate receptor, dimeric enkephalins, 21, 558

subunit, in tetrameric hemoglobin (rabbit), 21, 1

Sensitivity

heat, pituitary dopamine receptors (porcine), 22, 298

insulin, modulation by adenosine (rat), 22, 614

Serotonin

receptor, characterization in brain (rat), 22, 243

uptake, characterization, 21, 362, 368

Serotonin-2

binding sites, selective 3H-ligand for (rat), 21, 301

receptor binding sites (rat), 21, 301

Serum, human

albumin, characterization of drug binding area, 21, 387

binding to warfarin, 21, 100

interaction with cephalosporins, 21, 92

Sex differentiation, cytochrome P-450 (rat), 22, 795

Sexual differences, drug metabolism (rat), 21, 744

Skeletal muscle

action potential (frog, ray), 22, 82

carbonic anhydrase, carbon dioxide hydration activity (cat), 22, 211

SKF 525-A, see $-Diethylaminoethyl-2,2-diphenylpentanoate

SKF 10047, binding sites, 21, 266

Skin, neonatal, drug metabolism (rat), 21, 239

Sodium

channel

batrachotoxin binding, 22, 627

binding site in nerve membrane, 21, 343

conformation, 21, 343

828 SUBJECT INDEX

Sodium-continued

channel-continued

mutagenic effect, 22, 196

neuroblastoma variants, 22, 196

variants, 22, 196

effect on agonist and antagonist interactions with platelet alpha2-

adrenergic receptor (human), 21, 609


fluxes, in erythrocytes (turkey), 21, 503

ion, role in adenylate cyclase inhibition (rat), 22, 589

regulation of receptors (rat), 22, 532

Solubiity, lipid, ethanol, 22, 133

Solubilization, serotonin receptors in brain (rat), 22, 243

Somatostatin, effect on polymorphorphonuclear neutrophils (human),

21, 78Species heterogeneity, adenosine receptor binding (rat, rabbit, guinea

pig, calf, human), 22, 250

Spectroscopy, pulmonary cytochrome P-450 (rabbit), 22, 221

Spin trap, superoxide, 21, 262

Spiperone, binding in brain (rat), 22, 243

Spiroperidol, “H-labeled

binding in pituitary (porcine), 22, 290, 298

binding to caudate nucleus (calf), 22, 281

dopamine receptor binding (bovine), 21, 44, 52

Stability, epoxide, polycyclic aromatic hydrocarbons, 22, 459

Statistical analysis, computer modeling method, for radioligand binding

data, 21, 5

Stenosis, aortic, effect on cardiac muscarmnic receptors (rat), 21, 589

Stenotomus chrysops, cytochrome P-450 and monooxygenase activity

in cardiac microsomes, 21, 517

Stereoselectivity

differential, methotrimeprazine enantiomers, 21, 315

metabolism , chrysene 1,2-dihydriols (rat), 22, 182

Stereospecificity, carbomethoxy at position 10, 21, 196

Stilbene oxide, trans-, enzyme induction (rat), 21, 511

Striatum, catecholamine uptake system (rat), 21, 374

Structure-activity relationship

alkyl-substituted -y-butyrolactones (mouse, guinea pig), 22, 444

alkyl-substituted succinimides (mouse, guinea pig), 22, 444

amantadine (ray), 22, 82

anthracycline molecule, 21, 196

Ca2�-calmodulin complex, 22, 403

dopamine agonists (rat), 22, 281

in ansamycins, 21, 394

picrotoxinin (mouse, guinea pig), 22, 444

quantitative, 22, 725

anxiolytic drugs, 22, 11

molecular shape analysis, 21, 187

quantum chemical analysis, 22, 525

transport sites, hypothalamic and striatal catecholamine uptake, 21,

374

Submandibular gland, regulation of autonomic receptors (rat), 21, 27

Substance P

‘25I-labeled derivative, binding to mesencephalic cells (mouse), 22,48

receptors, in mesencephalic cells (mouse), 22, 48

Substituent constants, theorem, 22, 725

Substrate

amine pump (rat), 21, 374

dopamine inhibition, in striatum and hypothalamus (rat), 21, 374

Subunit selectivity, in tetrameric hemoglobin (rabbit), 21, 1

Succinimides, alkyl-substituted, structure-activity relationships

(mouse, guinea pig), 22, 444

Sulfation rates, 7-hydroxycoumarin (rat), 22, 509

Sulfhydryl group, effects on adenylate cyclase activation (dog), 22, 595

Sulfidocyclophosphamide, cytotoxicity, synergism with misonidazole

(mouse), 22, 175

Sulfite, horseradish peroxidase-hydrogen peroxide oxidation, 22, 732

Sulfonamide, inhibition of skeletal muscle carbonic anhydrase (cat),

22, 211

Sulfonylureas, hypoglycemic, Ca2� ionophoretic activity (mouse), 22,

715

Sulfoxidation

effect on neuroleptic potency of chlorpromazine, 21, 409

effect on neuroleptic potency of methotrimeprazine, 21, 409

Sulfoxide, metabolites, 21, 409

Sulfur dioxide, aqueous, sulfur trioxide radical anion, 22, 732

Sulfur trioxide, radical anion, direct detection during oxidation of

sulfite, 22, 732

Superoxide

hepatic microsomal (rabbit), 22, 471

spin-trapped adducts, 21, 262

Synaptic plasticity, 21, 280

Synaptosome

calcium uptake (rat, mouse), 22, 99

hypothalamic (rat), 21, 181

uptake system, 21, 374

membrane

cholinergic muscarmnic receptor (cat), 22, 304

potential (rat, mouse), 22, 99

striatal, uptake system (rat), 21, 374

Synergism, cytotoxic, misonidazole and sulfidocyclophosphamide(mouse), 22, 175

Synthetase, prostaglandin, co-oxidation, 21, 133

Synthesis, prostaglandin, inhibition (toad), 21, 142

T

Tamoxifen binding, cooperativity studies (rat), 21, 287

Temperature

dependence, benzodiazepine-receptor interaction (rat), 22, 20

effect on [“Hiflunitrazepam binding (rat), 21, 57

Terbium fluorescence, 22, 105

2,3,7,8-Tetrachlorodibenzo-p-dioxin, induction of cytochrome P,-450


Tetrahydro-fJ-carboline, effect on membrane fluidity, 22, 721

Tetramethylammonium, agonist action (ray), 22, 63

Tetrapeptide, opiate, conformational-energy studies, 22, 667

Thermodynamics

benzodiazepine binding (rat), 22, 20

receptor interactions (rat, rabbit, guinea pig, calf, human), 22, 250

Thermotropic properties, dipalmitoylphosphatidylcholine, 22, 133

Thiono-sulfur-containing compounds, effect on liver (rat), 21, 464

Thrombin, platelet protein phosphorylation (human), 21, 422

Thymidine

kinase

inhibition, 22, 231

regulation, 22, 231

rescue effects in methotrexate-treated cells (human), 21, 718

rescue, in methotrexate-treated cells (human), 21, 718

triphosphate, inhibition, 22, 231

Thymidylate kinase, virus-coded, 21, 432

Thymidylate synthetase

activity in L1210 ascites cells, 22, 760

blockers, 21, 224

levels in gastrointestinal tumor cells (human), 21, 723

Thymus

nuclear histones, effect of methylmercury(II) (calf), 22, 121

synaptosomal protein carboxymethyltransferase (calf), 21, 181

Thyroid

cell

culture (porcine), 21, 66, 73

muscarmnic cholinergic receptors on (porcine), 21, 66, 73

effect on cardiac muscarinic receptors (rat), 21, 589

Thyrotropin-stimulated cyclic AMP, in cultured thyroid cells (porcine),

21, 66

Time delay, cyclic AMP accumulation in lymphoma cells, 22, 609

Tissue, normal limiting (human), 22, 771

SUBJECT INDEX 829

Zinc, glucagon binding, 22, 105

Torpedo

electric organ

drug interactions, 22, 63

receptors, 22, 72

electroplax, receptors, 22, 82

Toxicity, see also Cytotoxicity

cardiac, anthracydline antineoplastic agents (rabbit), 22, 471

pulmonary, 4-ipomeanol (rabbit), 22, 738

renal, phenacetin metabolites, 22, 479

Toxin

bound molecules, exchange of tritium, 21, 343

cholera

ADP ribosylation (mouse), 22, 204


Temor, muscarinic agonist-induced (rat), 21, 594

Triarylmethane dye, cytochrome P450-dependent reduction (rat), 22,

239

Trifluoperazine, effect on human platelets, 21, 422

Tritium

back exchange, saxitoxin, 21, 343

exchange, from bound toxin molecules, 21, 343

Tryptamine, effect on membrane fluidity, 22, 721

Tumor

-derived methionine adenosyltransferases, differences in active-site

and potential target (rat), 22, 752

gastrointestinal

cytotoxicity of 5-fluorodeoxyuridine and methotrexate (human),

21, 723

thymidylate synthetase levels (human), 21, 723

Tyrosine aminotransferase, hepatic, effect of pregnenolone- 16a-carbo-

nitrile (rat), 21, 753

Tyrosine hydroxylase

effect on dopamine synthesis (rat), 21, 114

induction by glucocorticoids (mouse), 22, 421

U

Uptake, norepinephrine, inhibition by xylamine, 21, 380

Uracil, DNA incorporation, 21, 211

Uterus, estrogen receptor (rat), 21, 533

V

van’t Hoff plot, nonlinear, flunitrazepam (rat), 22, 20

Varicella zoster virus, inhibition by (E)-5-(2-bromovinyl)-2’-deoxyrur-

idine, 21, 432

Vas deferens

binding of $-endorphin, models (rat), 22, 657

histamine receptors (mouse), 22, 602

Vasopressin, effect on urinary bladder (toad), 21, 142

Vinblastine

Ca2ttransport ATPase inhibition (human), 22, 413

effect on water flow in urinary bladder (toad), 21, 142

Vinca alkaloids, Ca2�-transport ATPase inhibition (human), 22, 413

Vincristine, Ca2�-transport ATPase inhibition (human), 22, 413

Vindesine, Ca2�-transport ATPase inhibition (human), 22, 413

Virus

herpes simplex, inhibition by (E)-5-(2-bromovinyl)-2’-deoxyruridine,

21, 432

varicella zoster, inhibition by (E)-5-(2-bromovinyl)-2’-deoxyuridine,

21, 432

Voltage clamp

effect on nicotinic acetylcholine receptor (frog, ray), 22, 82


Voltage-sensitive ion channels, nicotinic acetylcholine receptor, 21, 351

W

Walker 256 carcinoma (rat), 21, 729

Warfarin

-albumin interaction, equilibrium and kinetics, 21, 100

binding to human serum albumin, 21, 100

high-affinity binding sites, 21, 387

Water flow, in urinary bladder (toad), 21, 142

x

Xanthines, binding in brain (rat, rabbit, guinea pig, calf, human), 22,

250

Xenograft

colon adenocarcinoma (human), 22, 771

colon, selectivity (human), 22, 771

X-Ray, structure determinations

chiorpromazine, 21, 409

imidazolidines, 21, 400

Xylamine

chemical transformations in solution, 21, 380

inhibition of norepinephrine uptake, 21, 380

Y

Yohimbine

“H-labeled


binding in renal cortex (rat), 22, 532

characterization of adenylate cyclase-coupled alpha�-adrenergic

receptors (rat), 22, 589

use as radioligand (human), 22, 574

z

1�

U.S. POSTAL. SERVICE

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION(Rqulrsd by 39 U.S.C. 3685)

1. TiTLE OF PUBLICATION

Molecular PharmacologyISSN A. PUBLICATION NO. 2. DATE OF FILING

� J� I 2 � 6 � 819 � � X 10/1/82

3. FREQUENCY OF ISSUE.

Bi-monthly

A. NO. OF ISSUES PUBLISHED B. ANNUAL SUBSCRIPTIONANNUALLY PRICE

6 Personal : $65.00Institutional: $130.01

4. COMPLETE MAILING ADDRESS OF KNOWN OFFICE OF PUBLICATION (Stri(, City, County, Stat. and ZIP Cod.) (Not prlnts.rs)

9650 Rockville Pike Bethesda, Maryland 20814

5. COMPLETE MAILING ADDRESS OF THE HEADQUARTERS OR GENERAL BUSINESS OFFICES OF THE PUBLISHERS (Not prlnt#{149}fs)

9650 Rockville Pike Bethesda, Maryland 20814

t FULL NAMES AND COMPLETE MAILING ADDRESS OF PUBLISHER. EDITOR. AND MANAGNG EDITOR (This It�n MUST NOT b. blank)

PUBLISHER (Nama and CompIf#{149}MblIbsgAddr.sa)

The American Society for Pharmacology 9650 Rockville Pikeand Experimental Therapeutics Bethesda, Maryland 20814

EDITOR (Nan* and CompI�. MailIng Addr.a)

Dr. Norman Kirshner Duke University Medical SchoolPharmacology Department Durham, North Carolina 21202

MANAGING EDITOR (Nama �,d CompM(#{149} M&Ilng Addrass)

Kay A. Croker, Executive Officer 9650 Rockville PikeAmerican Society for Pharmacology & Experimental Therapeutics Bethesda, Maryland 20814

7. OWNER (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholdersowning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must

be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publica-

tion is published by a nonprofit organization, its name and address must be stated.) (Item must be completed)

FULL NAME COMPLETE MAILING ADDRESS

American Society for Pharmacoloqy#{225}#{241}��xperimenta I neraoeutics

FULL NAME

9650 Rockville Pikebetnescia. Maryland �Uli14

8. KNOWN BONDHOLDERS. MORTGAGEES, AND OTHER SECU

TOTAL AMOUNT OF BONDS. MORTGAGES OR

R�TY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF

OTHER SECURITIES (It thr ar none, ao state)

9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Section 411.3, DMM only)The purpose, funct,on. and nonprofit status of fhis organizafion and the exem t status for Federal income tax purposes (Check on.)

(1) (2)r��i HAS NOT CHANGED DURING -- HAS CHANGED DURING (II changed, publlshr must submIt explanation ofL.AJ PRECEDING 12 MONTHS U PRECEDING 12 MONTHS change with this statement.)

10. EXTENT AND NATURE OF CIRCULATtONAVERAGE NO. COPIES EACHISSUE DURING PRECEDtNG

12 MONTHS

ACTUAL NO. COPIES OF SINGLEISSUE PUBLISHED NEAREST TO

FILING DATE

A.TOTALNO.COPIE5(Nifprsisflun) 2112 2175

8. PAID CIRCULATION1. SALES ThROUGH DEALERS AND CARRIERS. STREETVENDORS AND COUNTER SALES none none

2. MAIL SUBSCRIPTION

1665 1782

C. TOTAL PAID CIRCULATION (Sum of 1081 and 1�2)i 665 1782

D. FREE DISTRIBUTiON BY MAIL, CARRIER OR OTHER MEANSSAMPLES, COMPLIMENTARY. AND OTHER FREE COPIES 86 75

E. TOTAL DISTRIBUTION (Sum ol C and 0) 1 7 5 1 1857

F. COPIES NOT DISTRIBUTED1. OFFICE USE, LEFT OVER, UNACCOUNTED, SPOILEDAFTER PRINTING

36 1 318

RETURN FROM NEWS AGENTS none none

G. TOTAL (Sum of E. Fl and 2 - should equal net press run shown in A) 2 1 1 2 2175

SIGNATUR/AND TITLE OF EDITOR. PU8LISHER. BUSINESS11. I certify that the statements made by�’�J MANAG ,OR OWNER

me above are correct and complete � ((� Q � I �

COMPLETE MAILING ADDRESS

INSTRUCTIONS TO AUTHORS

assigned exclusively to the Society for Pharmacology and Experi-

Molecular Pharmacology will publish the results of investigations that shed significant light on drug action

or selective toxicity at the molecular leveL The term “drug” is defined broadly to include chemical agents that

selectively modify biological function.

Suitable papers are those which describe applications of the methods of biochemistry, biophysics, genetics,

and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental

investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for

further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon

underlying molecular interactions are not regarded as appropriate for publication.

Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture;

conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and

macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of

action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular

structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and

other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis;

pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species;

drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and

transport of drug molecules between biological compartments.

“Short Communications” will be considered for rapid publication if their subject matter lies within the scope

of the Journal, if they are concise, and if they are considered to be of sufficiently immediate importance to the

work of other investigators to justify accelerated publication. They may contain experimental observations,

theoretical material, or significant comment upon published investigations.

Page charges. Authors will be billed at the rate of $30.00 per

page after the paper has been published. It is expected that the page

charge will be paid if funds are available for that purpose from the

author’s institution or from the sponsor of this research. Payment

of the charge is not a condition for publication. Neither the editors

nor the reviewers will have knowledge as to who has paid the

charge, and this payment always will be considered entirely volun-

tary.

Submission ofmanuscript. Manuscripts are published in English

only and should be sent to the Editor, Dr. Joel Hardman, Editor,

Molecular Pharmacology, Department of Pharmacology,

Vanderbilt University Medical Center, Nashville, Tennessee

37232, U. S. A. Manuscripts should be typewritten double-spaced

with ample margins on one side of the paper, 8#{189}x 11 inches (ca.

215 x 280 mm). Submit four complete copies of the manuscript and

four copies of each figure, plus one original drawing or photograph

of each figure. Each half-tone figure requires four original drawings

or photographs. All pages should be numbered consecutively begin-

ning with the title page. Limit your reference listings to the minimal

number required to adequately document the manuscript. In most

instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return

only their comments to the editorial office and to destroy manu-

scripts after a fmal decision on their acceptability has been made.

Original figures and single copies of manuscripts not accepted for

publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain

will not have been published previously and are not being submitted

elsewhere. Manuscripts are accepted for review with the under-

standing that all persons listed as authors have given their approval

for the submission of the paper; further, that any person cited as a

source of personal communications has approved such citation.

Written authorization may be required at the Editor’s discretion.

Articles and any other material published in Molecular Pharma-

cology represent the opinions of the author(s) and should not be

construed to reflect the opinions of the Editor(s) and the Publisher.

If and when a manuscript is published, it will become the sole

property of the Journal.

Authors submitting a manuscript do so on the understanding that

if it is accepted for publication, copyright in the article, including

the right to reproduce the article in all forms and media, shall be

mental Therapeutics. No reasonable request by the author for

permission to reproduce any of his or her contributions to the

journal wifi be refused.

Organization and style ofmanuscripts. The policy of the Journal

is to allow authors maximum freedom in organizing and presenting

their material, and in expressing their ideas, provided only that

clarity and conciseness are achieved.

Certain conventions must be observed. Chemical and mathemat-

ical formulas and abbreviations should follow the Instructions to

Authors ofthe Journal ofBiological Chemistry (Vol. 256, pp. 1-11,

January 10, 1981). Drugs must be referred to by their generic or

chemical names throughout the text, but may be identified by trade

name in parentheses or a footnote. The systematic name and

number given by the Commission on Enzymes of the International

Union of Biochemistry should be included for each enzyme of

importance in a paper, at the point in the Summary or Introduction

where the enzyme is first mentioned. The use of abbreviations

should be minimized and abbreviations avoided in the Summary.

All essential abbreviations should be defined in a single footnote

when first introduced. Abbreviations of journal names should con-

form to the style of BiologicalAbstracts. References to papers that

have been accepted for publication, but have not appeared, should

be cited like other references with the abbreviated name of the

journal followed by the words “in press.” Copies of such papers

should be sent whenever the findings described in them have a

direct bearing on the paper being submitted for publication. “Per-

sonal Communications” and “Unpublished Observations” should be

cited in footnotes to the text and should not be included in the

reference list.

A manuscript should include the following, in the order listed: (1)

Title. Numbered footnotes to the title should be avoided; acknowl-

edgment of financial support should be given in an unnumbered

footnote to the title. (2) Names of authors, their laboratory and

institution. (3) A running title, not exceeding 60 characters and

spaces. (4) Summary. (5) Text. Footnotes should be referred to by

superscript numbers and references by numbers in parentheses. (6)

References, numbered according to order of citation in the text,

including title and complete pagination. Examples: 1. Goren, J. H.,

L. G. Bauce, and W. Vale. Forces and structural limitations of

binding of thyrotropin-releasing receptor: the pyroglutamic acid

moiety. Mol. Pharmacol. 13:606-614 (1977). 2. Sandler, M. Varia-

tions in monoamine oxidase activity in some human disease states,

in Monoamine Oxidase and Its Inhibition. Ciba Foundation Sym-

posium 39. Elsevier, Amsterdam, 327-340 ( 1976). (7). Footnotes,

numbered according to order of appearance in the text. (8) Tables.

(9) Figures. (10) Legends to figures. (11) Name and address of

person to receive galley proof.

Tables. These should be numbered with arabic numerals and

designed to fit the single-column width of the full-page width. Every

table should have an explanatory title and sufficient experimental

detail in a paragraph following the title to be intelligible without

references to the text (unless the procedure is given in the Methods

section, or under another table or figure). Footnotes to tables should

appear beneath the tables themselves and should be designated by

lower-case italic superscript letters, a, b, c, etc.

Figures. These should be numbered with arabic numerals. Each

of the four manuscript copies should contain all of the figures. Only

the orignal set need be of quality suitable for reproduction except in

the case of half-tones, which require four sets of photographs or

original drawings. These should be unmounted glossy photographs

(or original India-ink drawings). Usually figures will be reduced to

one column width (85 mm) and all numbers after such reduction

should be at least 1.5 mm high. The figures must be ready, in all

respects, for direct reproduction: no lettering or other art work will

be done by the publisher. If symbols are not explained on the face

of the figure, only standard characters, of which the printer has

type, may be used (x, 0, #{149},El, �, �, A, C). The back of each

photograph should bear its number, and the legend TOP at the

appropriate edge. The list of legends for the figures should give

captions and sufficient experimental detail, as required for tables.

Galley proof. The cost of all changes on galley proof, other than

printer’s errors, will be charged to authors. The Editors are very

much interested in having accepted contributions appear in the

earliest possible issue of the Journal, and therefore request that

galley proof be returned within 24 hours after its receipt. In excep-

tional cases, a “Note added in proof” may be attached and will be

published if the Editor approves.

Reprints and page charges. An order form for reprints as well as

information on the estimation of page charges will be mailed with

galley proof. Please direct questions on reprints, page charges, or

other business matters to Kay Croker, Executive Officer, American

Society for Pharmacology and Experimental Therapeutics, 9650

Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.

Affolter, Burt, Stanley. Aguilar, - Molecular...

Documents

Transcript of Affolter, Burt, Stanley. Aguilar, - Molecular...